

Gil Y. Melmed, M.D., M.S.

CURRICULUM VITAE

(Updated July, 2018)

BUSINESS ADDRESS

Cedars-Sinai Medical Center
Division of Gastroenterology/IBD Center
8730 Alden Dr.
Thalians Bldg 2E
Los Angeles, CA 90048
Phone: (310) 423-4100
E-mail: melmedg@cshs.org

EDUCATION

University of Pennsylvania (Philadelphia, PA). 1992-1995
Bachelor of Arts, Biological Basis of Behavior
Magna cum Laude

Albert Einstein College of Medicine, Bronx NY. 1996-2000
Doctor of Medicine M.D.
Elected to *Alpha Omega Alpha* (1999)

Internal Medicine 2000-2003
Cedars-Sinai Medical Center, Los Angeles
University of California, Los Angeles

Gastroenterology fellowship 2003-2006
University of California, Los Angeles

Master's of Science in Clinical Research 2004-2006
UCLA School of Medicine
Department of Biomathematics, K30 Program

MEDICAL LICENSURE

California #A78742

CERTIFICATION

American Board of Internal Medicine,
Gastroenterology 2006 - present

PROFESSIONAL EXPERIENCE

Present Positions
Director, Clinical Inflammatory Bowel Disease 2013 - present
Director, Clinical Trials 2008 - present
Inflammatory Bowel Disease Center
Cedars-Sinai Medical Center

Health Sciences Clinical Professor of Medicine <i>David Geffen School of Medicine at UCLA</i>	2017 -
Health Sciences Associate Clinical Professor	2013 – 2017
Health Sciences Assistant Clinical Professor	2008 – 2013
Clinical Instructor of Medicine	2007 – 2008
Director, IBD Advanced Fellows Training, CSMC	2011 - 2018

PROFESSIONAL ACTIVITIES

Committee Services:

Cedars-Sinai:	Curriculum Committee, GI Fellow representative	2004 - 2006
	GI Endoscopy Unit Management Committee, Member	2007- present
	Cedars-Sinai Leadership Development Committee	2009-2010
	Inflammatory Bowel Disease Center of Excellence	2009-2010
	CS-Link Electronic Health Record Committee, Member	2009- 2015
	Cedars-Sinai <i>Clostridium Difficile</i> Task Force Member	2010-2011
	Cedars-Sinai Leadership Development Committee, Co-Chair	2010-2014
	Cedars Sinai Ambulatory Care Leadership Committee	2014-present

Grant Review Committees:

CCFA Clinical Research Alliance Grant Review Committee	2013 - 2017
<i>Ad hoc</i> Reviewer, Swiss National Science Foundation	2015
<i>Ad Hoc</i> Reviewer, UCB Pharma (Union Chimique Belge) – Fellow Grants for IBD Research	2009, 2011-13
<i>Ad Hoc</i> Reviewer, Alberta Children’s Hospital Foundation Funding Competition	2011

Other Committee Services:

American College of Gastroenterology – Member of Practice Management Committee	2006 – 2011
Crohn’s and Colitis Foundation of America (CCFA) – Co-Chair of Medical Advisory Committee, Los Angeles Chapter	2008-2014
CCFA National Professional Ed. Committee Member	2009 – present
CCFA National Scientific Advisory Committee: Quality of Care Committee (Co-Chair)	2012 – 2018
American College of Gastroenterology Research Com.	2012 – 2013
American Gastroenterology Association Quality Measures Committee Chair, IBD Section	2014-2015
Vice Chair of Building Research in IBD Globally”	2007-

Community Service:

CCFA Co-Chair of LA Patient Education Symposium	2007-2014
CCFA LA Chapter Medical Advisory Committee Member	2007-

Societies / Memberships:

<i>Alpha Omega Alpha</i> , Medical Honors Society	1999 - present
American Gastroenterological Association (Fellow)	2002 - present

American Board of Internal Medicine, Diplomate	2003
American College of Gastroenterology	2005 - present

Abstract Review Committees:

Digestive Disease Week; American Gastroenterology Association; Immunology, Microbiology and Inflammatory Bowel Diseases (IMIBD); Uncontrolled Therapeutic Observations section	2008 - 2016
Digestive Disease Week; American Gastroenterology Association; Quality of Care / Patient reported outcomes	2015 -2016
Crohn's and Colitis Foundation of America Advances in IBD, Annual Meeting, Clinical Research	2012, 2013

Editorial Board:

<i>American Journal of Gastroenterology</i> , Assoc. Editor	2015 - 2018
<i>Inflammatory Bowel Disease</i> , Clin. Research Section Ed.	2009 - 2015

Journal Reviewer (Ad hoc)

<i>Inflammatory Bowel Disease</i>	2007 - present
<i>American Journal of Gastroenterology</i>	2007 - present
<i>Digestive Disease and Science</i>	2008 - present
<i>IBD Monitor</i>	2009 - present
<i>Journal of Crohn's and Colitis</i>	2009 - present
<i>Alimentary Pharmacology and Therapeutics</i>	2009 - present
<i>Clinical Gastroenterology and Hepatology</i>	2010 - present
<i>Gastroenterology</i>	2010 - present
<i>JAMA</i>	2012 - present

Meeting Organizer

CSMC Medical Staff Annual Leadership Development Retreat	2010-2014
IBD2020USA (New Orleans, LA)	May, 2014
IBD Quality of Care, Bi-Annual Learning Sessions	May, 2015-18

Data Safety Monitoring Board

PROTECT Study (NIH/NIDDK)	2013 – 2017
RHB104 (RedHill Biopharma)	2016 – present
PREVENT study (Janssen)	2012-2015
Ozanimod RPC 2201/3101/3102 (Receptos/Celgene)	2015 – present
Ozanimod RPC 3201/3202/3203/3204 (Celgene)	2018 – present

HONORS AND AWARDS

Rose Award for Excellence in Undergraduate Academic Research, Univ. Pennsylvania	1995
<i>Alpha Omega Alpha</i> Student Research Award, Albert Einstein College of Medicine	1999
Solomon Scholars Resident Research Award (UCLA)	2001, 2002
Rubenstein Resident Research Award, Second Place (CSMC)	2002
NIH Institutional Training Grant Recipient (T32 DK07180), UCLA Digestive Diseases	2004-2006
American College of Gastroenterology/Centocor award for Top 5 Abstracts in IBD	2005
North American Conference of Gastroenterology Fellows, Outstanding Research Award	2005, 2006
Crohn's and Colitis Foundation of America, Clinical Research Award	2008

American College of Gastroenterology: Presidential Poster Award, San Diego, CA	2009
Southern California's Best Doctors, Los Angeles Magazine	2009-2017
Excellence in Teaching and Mentorship Award, UCLA GI Fellowship Program	2011

Patents:

1. Fleshner/Vasiliauskas/Melmed/Targan. Ileal Pouch-Anal Anastomosis (IPAA) Factors in the Treatment of Inflammatory Bowel Disease. *United states patent number: 20100105044* (2010)
2. Rezai/Pimentel/Melmed. Ultraviolet therapy. *United States provisional patent number 62/343,710* (2016)

RESEARCH SUPPORT**Active/Ongoing:****Grants**

Crohn's and Colitis Foundation	01/01/2015 – 12/31/2020	6.0 calendar
Role: Co-Principal Investigator	Annual (Direct): \$183,338	
Title: CCFA Quality of Care Program for Adult Patients with Inflammatory Bowel Disease.		
Pfizer	01/02/2018 – 01/01/2020	1.2 calendar
Role: co-Principal Investigator	Annual (Direct): \$194,131	
Other co-PI's: Spiegel, Almario; Grant ID 37998665		
Title: IBD&me: Optimizing Selection of Biologic and Small Molecule Therapies in IBD		
Miraca Life Sciences, Inc.	04/13/2018-04/12/2021	0.12 calendar
Role: Site PI	Annual: \$4,615	
Title: Therapeutic drug monitoring of anti-TNF maintenance therapy in patients with inflammatory bowel disease: A prospective, multi-center study to compare two different assays		
AHRQ 1R01HS021747-01	08/01/2013 – 07/31/2018	0.12 calendar
Role: Co-Investigator, Site PI	Annual: \$1,000	
Title: Crohn's Shared Decision-Making Program		

Clinical Trials

Janssen Pharmaceuticals	11/30/2015 – 01/31/2022	0.72 calendar
Role: Site PI	Annual: \$28,186	
Title: (Protocol CNTO1275UCO3001) A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis		
Gilead Sciences, Inc.	11/10/2017 – 11/09/2020	0.12 calendar
Role: Site PI	Annual : \$10,807	
Title: (Protocol GS-US_419-3896) A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn's Disease.		

Gilead Sciences, Inc. Role: Site PI Title: (Protocol GS-US-418-3899) A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis.	11/10/2017 – 11/09/2020 Annual: \$13,865	0.12 calendar
Gilead Sciences, Inc. Role: Site PI Title: (Protocol GS-US-419-3895) Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn's Disease.	08/04/2017 – 08/03/2020 Annual: \$44,211	0.36 calendar
Gilead Sciences, Inc. Role: Site PI Title: (Protocol GS-US-418-3898) Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Ulcerative Colitis.	08/04/2017 – 08/03/2020 Annual: \$72,617	0.36 calendar
Atlantic Pharmaceuticals Ltd. Role : Site PI Title: (Protocol ACH UCP-301) A Randomised, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Topical Alicaforsen Enema in Subjects with Active, Chronic, Antibiotic Refractory Primary Idiopathic Pouchitis	02/29/2016 – 02/28/2019 Annual : \$42,403	0.12 calendar
Takeda Development Center Americas Role : Site PI Title: (Protocol C13008) A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Patients with Ulcerative Colitis and Crohn's Disease.	10/05/2009-12/31/2018 Annual : \$24,463	0.24 calendar
Janssen Pharmaceuticals Role : Site PI Title: (Protocol CNTO1275CRD3003) A Phase 3 Open Label Studies to Determine the Short- and Long-term Safety and Efficacy of Ustekinumab in Patients with Crohn's Disease.	10/11/2012-09/30/2018 Annual : \$24,121	0.24 calendar
Pfizer Pharmaceuticals Role : Site PI Title: (Protocol A3921139) Phase 3 Open Label Studies to determine the Short- and Long-term Safety and Efficacy of Tofacitinib in Patients with ulcerative colitis.	05/29/2012 – 07/31/2018 Annual : \$16,002	0.12 calendar

Inactive/Completed:**Grants**

Shire Pharmaceuticals Role: PI Title: Multidisciplinary Care for IBD	08/01/2013 – 05/31/2018 Annual: \$59,000	
Prometheus Labs Role: PI Title: The Steady-State Pharmacokinetics of Adalimumab (RES-COL13ADA05)	04/21/2014 – 4/20/2017 Annual: \$1,227	0.12 calendar
Janssen Pharmaceuticals and Abbott Role: Site PI	03/20/2013 – 03/19/2015 Annual: \$1,750	0.12 calendar

Title: IBD-OPERA Database – Inflammatory Bowel Disease – Outcomes, Preferences, Educations, Resource Utilization, Assessment Database

Crohn’s and Colitis Foundation 07/01/2013 – 12/31/2014 0.6 calendar
 Role: Site PI Total for project period: \$38,665
 Multicenter pilot program to evaluate the feasibility of a Learning Health Collaborative Network to improve the quality of care for adults with inflammatory bowel disease.

Shire Development LLC 12/01/2012 – 09/30/2013 0.12 calendar
 Role: Site PI Annual: \$4,028
 Sepulveda Research Corporation
 Title: Measuring Health-Related Quality of Life in the Diverticular Disease: Empirical Validation of the DV-QOL Instrument

Phantasos Foundation. 09/01/2011 – 09/01/2012 0.6 calendar
 Fidelity Fund Annual: \$8,800
 Role: PI
 Title: Humoral Immune response to pertussis reactivation and tetanus vaccines in adult patients with inflammatory bowel disease.

Marceled Foundation. 08/2010 – 08/2012 0.6 calendar
 Role: PI Annual: \$3,200
 “Long-Term Follow-up of Response to Pneumococcal Vaccination in Patients with Inflammatory Bowel Disease.”

U01 NIH/NIAMS 08/01/2011 – 07/31/2012 0.72 calendar
 AR057936A Annual: \$18,430
 Role: Co-Investigator, Site PI
 Title: Patient Reported Outcomes Measurement Information System (PROMIS) Network Study Protocol

Crohn’s and Colitis Foundation of America 07/01/2008 – 06/30/2011 0.6 calendar
 Role: PI Annual: \$3,234
 Title: Response to Infliximab for Active Ulcerative Colitis (UC): Repository to Collect Specimens and Clinical Data from UC Patients Receiving Infliximab (REACT Study).

Centocor 05/01/2006 – 12/31/2008 0.12 calendar
 Role: PI Annual: \$6,000
 Title: Determining the minimally important difference in Crohn’s disease: A prospective estimation of the MID for the Crohn’s Disease Activity Index, the Inflammatory Bowel Disease Questionnaire, and the Harvey-Bradshaw Index.

IOIBD Grant 12/01/2005 – 11/30/2006 0.6 calendar
 International Organization for Inflammatory Bowel Disease
 Role: Trainee investigator \$12,000
 Principal Investigator, Stephan Targan

Clinical Trials

Celgene Corporation 10/17/2017 – 05/31/2018

Role: Site PI	Annual: \$10,807	
Title: (Protocol GED-0301-CD-003) A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects with Active Crohn's Disease.		
Celgene Corporation	01/23/2017 – 05/31/2018	0.12 calendar
Role: Site PI	Annual: \$15,123	
Title: (Protocol GED-0301-CD-002) A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Subjects with Active Crohn's Disease		
Celgene Corporation	02/06/2018 – 03/21/2018	
Role: Site PI	Annual: 7,000	
Title: (Protocol GED-0301-CD-004) Phase 3, Long-Term Active Treatment Extension Study of Mongersen (GED-0301) in Subjects with Crohn's Disease.		
Celgene Corporation	02/12/2015 – 02/11/2018	0.7 calendar
Role: Site PI	Annual: \$15,391	
Title: (Protocol GED-0301-CD-001) A Randomized, Double-Blind, Multicenter Study to Explore the Effect of GED-0301 on Endoscopic and Clinical Outcomes in Subjects with Active Crohn's Disease.		
Luitpold Pharmaceuticals, Inc.	07/10/2014 – 07/09/2017	0.12 calendar
Role: Site PI	Annual: \$6,275	
Title: (Protocol 1VIT13035) A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer (Ferric Carboxymaltose) vs. Oral Iron to Baseline Hepcidin Levels in Patients with Iron Deficiency Anemia (IDA) secondary to Inflammatory Bowel Disease (IBD) or Gastric Bypass.		
Gilead Sciences	07/10/2015 – 06/01/2017	0.44 calendar
Role: Site PI	Annual: \$45,173	
Title: (Protocol GS-US-395-1663) A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects with Moderately to Severely Active Crohn's Disease.		
Given Imaging	03/03/2014 – 02/28/2017	0.12 calendar
Role: Site PI	Annual: \$19,910	
Role: Overall study PI, local site PI		
Title: (Protocol MA-209) Monitoring Disease Activity Using Video Capsule Endoscopy (VCE) in Crohn's Disease (CD) Subjects		
Nutrition Science Partners	11/01/2013 – 10/31/2016	0.12 calendar
Role: Site PI	Annual: \$4,051	
Title: (Protocol HMPL-004-04) Phase III, Double-Blind, Multi-Center, Placebo-controlled Maintenance Trial of HMPL-004 in Subjects with Mild to Moderate Ulcerative Colitis with Clinical Remission or Response from Induction Therapy (NATRUL-4)		
Pfizer Pharmaceuticals	05/29/2012 – 07/31/2016	0.12 calendar
Role : Site PI	Annual : \$4,350	
Title: (Protocol A3921096) Phase 3, Maintenance Study to determine the Short- and Long-term Safety and Efficacy of Tofacitinib in Patients with ulcerative colitis.		
Pfizer Pharmaceuticals	05/29/2012-06/30/2016	0.12 calendar
Role : Site PI	Annual : \$21,339	

Title: (Protocol A3921094) Phase 3, Induction Study to determine the Short- and Long-term Safety and Efficacy of Tofacitinib in Patients with ulcerative colitis.

Nutrition Science Partners 03/03/2014 – 03/02/2016 0.12 calendar

Role: Site PI Annual: \$15,332

Title: (Protocol HMPL-004-03) Phase III, Randomized, Multi-Centre, Double-Blind, Placebo-Controlled Trial of HMPL-004 in Subjects with Mild to Moderate Active Ulcerative Colitis (NATRUL-3)

Celgene Corporation 01/01/2011 – 12/31/2015 0.24 calendar

Role: Site PI Annual: \$11,548

Title: (Protocol CCT-PDA001-003) A Phase 1B, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults with Moderate-To-Severe Crohn's Disease

Telsar Pharmaceuticals 12/11/2012-12/10/2015 0.12 calendar

Role : Site PI Annual : \$2,433

Title: (Protocol 3291-CL-0004) A Phase 2, Induction Study to Determine the Safety and Efficacy of ASP3291 in Patients with Ulcerative Colitis.

Abbott 05/12/2008 – 07/31/2015 0.12 calendar

Role: Site PI Annual: \$6,065

Title: (Protocol P06-134) A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA (Adalimumab) in Subjects with Moderately to Severely Active Crohn's Disease (CD).

Celgene Cellular Therapeutics 07/06/2010 – 05/31/2015 0.36 calendar

Role: Site PI Annual: \$61,634

Title: (Protocol CCT-PDA001-002) A Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults with Moderate-To-Severe Crohn's Disease.

Janssen Pharmaceuticals 10/11/2012-10/30/2014 0.24 calendar

Role : Site PI Annual : \$37,210

Title: (Protocol CNTO1275CRD3001) A Phase 3, Induction, Maintenance Studies to determine the Short- and Long-term Safety and Efficacy of Ustekinumab in Patients with Crohn's Disease who have failed or are intolerant to TNF Antagonist Therapy.

Janssen Pharmaceuticals 10/11/2012 – 10/30/2014 0.24 calendar

Role : Site PI Annual : \$5,275

Title: (Protocol CNTO1275CRD3002) A Phase 3, Induction, Maintenance Studies to Determine the Short- and Long-term Safety and Efficacy of Ustekinumab in Patients with Crohn's Disease.

Takeda Development Center Americas 09/15/2009-08/31/2013 0.24 calendar

Role : Site PI Annual : \$20,630

Title: (Protocol C13006) A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by MLN0002 in Patients with Moderate to Severe Ulcerative Colitis.

Celgene Cellular Therapeutics 02/24/2009 – 02/23/2012 0.36 calendar

Role: Site PI Annual: \$24,891

Title: (Protocol CCT-PDA001-001) A Phase 1, Multi-Center, Open-Label, Dose-Escalation Study to Evaluate the Safety of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults with Moderate-to Severe Crohn's disease that is Refractory to Oral Corticosteroids and Immune Suppressants.

Centocor 05/11/2009 – 05/10/2011 0.36 calendar
 Role: Site PI Annual: \$26,994

Title: (Protocol CERTIFI C0743T26) A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to evaluate the efficacy and Safety of Ustekinumab in Subjects with Moderately to Severely Active Crohn's Disease previously treated with TNF Antagonist Therapy.

Bristol-Myers Squibb 08/23/2007 – 10/21/2010 0.36 calendar
 Role: Site PI Annual: \$4,426

Title: (IM101-084-079) A Phase III, Multi-Center, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with Abatacept in subjects with Active Crohn's Disease (CD) who have an Inadequate Clinical Response and/or Intolerance to Medical Therapy.

Bristol-Myers Squibb 08/16/2007 – 8/27/2009 0.36 calendar
 Role: Site PI Annual: \$3,600

Title: (Protocol IM101-108-068) A Phase III, Multi-Center, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with Abatacept in subjects with Active Ulcerative Colitis (UC) who have an Inadequate Clinical Response and/or Intolerance to Medical Therapy.

PENDING

AbbVie Inc. 07/01/2018 – 06/30/2021 0.36 calendar
 Role: Site PI Annual estimate: \$35,000

Title: (Protocol M16-067) A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Ulcerative Colitis Who Have Failed Prior Biologic Therapy.

AbbVie Inc. 08/01/2018 – 07/31/2022 0.36 calendar
 Role: Site PI Annual estimate: \$20,000

Title: (Protocol M16-066) A Multicenter, Randomized, Double-Blind, Placebo-Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis Who Responded to Induction Treatment in M16-067 or M16-065.

INVITED LECTURES AND PRESENTATIONS (Selected)

1. "Predicting the misdiagnosis of colitis". Cedars-Sinai Medical Center, Grand Rounds, Division of Gastroenterology. Los Angeles, CA, June, 2006
2. "Predicting the misdiagnosis of colitis". UCLA Masters Thesis Presentation / Defense, Division of Digestive Disease. Los Angeles, CA, June, 2006
3. "Why do pouches fail?" Cedars-Sinai Medical Center, Grand Rounds, Division of Gastroenterology. Los Angeles, CA, April 2007
4. "Top Down vs Step Up Approach for the Treatment of Crohn's Disease – PRO". Crohn's and Colitis Foundation of America CME Meeting. Los Angeles, CA, March 2008
5. "TNF blockers and immunomodulators impair antibody responses to pneumococcal polysaccharide vaccine in patients with IBD". Cedars-Sinai, Grand Rounds, Gastroenterology. Los Angeles, CA, May 2008
6. "Surgical Complications after Ileal Pouch Anal Anastomosis". Cedars-Sinai Medical Center Annual CME Conference. Lake Tahoe, CA, Sept 2008
7. "Capsule Endoscopy". Cedars-Sinai Annual CME Conference. Lake Tahoe, CA, Sept 2008

8. "Vaccination Issues in IBD", Western Canada 7th Annual Conference in Inflammatory Bowel Disease. Lake Louise, Alberta, Canada. Nov 2008
9. "Vaccination in IBD: What, when, and why". Crohn's and Colitis Foundation of America (CME Meeting). Chicago, IL. April 2009
10. "Vaccination and immunization issues for Patients with IBD", Crohn's and Colitis Foundation of America (Patient Education Meeting), Chicago, IL. April 2009
11. "Vaccination strategies in patients with inflammatory bowel disease", Crohn's and Colitis Foundation of America CME Meeting. Los Angeles, CA. April 2009
12. "Vaccination and immunization of IBD patients". Cedars-Sinai Medical Center, Grand Rounds, Division of Gastroenterology. Los Angeles, CA, May 2009
13. "An ounce of Prevention – Vaccination Strategies in Patients with IBD". Cedars-Sinai Medical Center, Gastroenterology Annual CME Conference. Los Angeles, CA, Oct 2009
14. Moderator of Panel Discussion for IBD Cases. Cedars-Sinai Medical Center, Gastroenterology Annual CME Conference, Oct 2009
15. "How to Discuss Risks of Biologic Therapy", Mentoring In IBD. Palm Springs, CA. March 2010
16. "Risks and Benefits in IBD". Crohn's and Colitis Foundation of America (CCFA) Patient Education Lecture. Los Angeles, CA. May 2010
17. "Vaccination Issues in IBD". Crohn's and Colitis Foundation of America (CCFA) Patient Education Lecture. Los Angeles, CA. May 2010
18. "Controversies in IBD". So. Cal. Society of Gastro 'Post DDW' Conference. Laguna Niguel. CA. July 2010
19. "State of the Art Lecture: Vaccination Issues in IBD: Role of the Gastroenterologist". Southern California Society of Gastroenterology 'Post DDW' Conference. Laguna Niguel, CA. July 2010
20. "Inflammatory Bowel Disease Update 2010". Ventura County Med Ctr Grand Rounds. Ventura, CA. Aug 2010
21. "How much room is there for Quality Improvement in IBD?" Crohn's and Colitis Foundation of America (CCFA) Quality Improvement Meeting. Las Vegas, NV. Oct 2010
22. "Positioning serologies and metabolites in your practice". UC Irvine Annual Conference. Las Vegas, NV. Oct 2010
23. "Vaccination issues in IBD". University of Toronto: Mentoring in IBD. Toronto, Canada. Nov 2010
24. "Vaccination issues in IBD". Crohn's and Colitis Foundation of America (CCFA). Advances in IBD. Hollywood, FL. Dec 2010
25. "Everyone Does It: Probiotics in IBD". Crohn's and Colitis Foundation of America (CCFA) Advances in IBD. Hollywood, FL. Dec 2010
26. Challenges in the Clinical Management of IBD Patients (Webinar). Crohn's and Colitis Foundation of America Mar 2011
27. "Treatment of post-operative Crohn's disease". Cedars-Sinai Medical Center, Gastroenterology Annual CME Conference. Los Angeles, CA, Mar 2011
28. "Predicting the prognosis of Crohn's disease". Sutter Health Annual CME Gastroenterology Meeting. Sacramento, CA. Mar 2011
29. "Quality Improvement in IBD: Building the Floor". Cedars-Sinai Medical Center, Gastroenterology Grand Rounds. Los Angeles, CA, Apr 2011
30. "Infliximab for severe hospitalized ulcerative colitis – Pro and Con". Digestive Disease Week, American Gastroenterology Association, Invited Lecture. Chicago, IL. May 2011
31. "Immunizations for IBD: Who, what, and when?". Canadian Nurses Association. Toronto, Canada. June 2011
32. "Controversies in IBD". Southern California Society of Gastroenterology "Post Digestive Disease Week" Conference. Laguna Beach, CA. July, 2011
33. "State of the art lecture: Management of Postoperative Crohn's Disease". Southern California Society of Gastroenterology "Post DDW" Conference. Laguna Beach, CA. July 2011

34. "Healthcare maintenance for women with immune disorders". Women with Chronic Immune Disorders CME Conference. San Francisco, CA. Aug 2011
35. "Developing a Checklist for Preparing Women for Therapy". Women with Chronic Immune Disorders CME Conference. San Francisco, CA. Aug 2011
36. "What is Quality of Care in IBD?". Alberta Society of Gastroenterology Annual General Meeting. (*Lecture available on video at <http://vimeo.com/30695627>*). Edmonton, AB. Sept 2011
37. "Healthcare maintenance for women with immune disorders". Women with Chronic Immune Disorders CME Conference. New York, NY. Sept 2011
38. "Developing a Checklist for Preparing Women for Therapy" Women with Chronic Immune Disorders CME Conference. New York, NY. Sept 2011
39. "Vaccinations and health maintenance for patients with IBD". American College of Gastroenterology Annual Postgraduate Course. Washington D.C., Oct 2011
40. "Prevention and treatment of infections in IBD". Advances in Inflammatory Bowel Diseases Clinical & Research Conference. Hollywood, FL. Dec 2011
41. "Prevention of thrombotic complications of IBD". Advances in Inflammatory Bowel Diseases Clinical & Research Conference. Hollywood, FL. Dec 2011
42. "Vaccination and Healthcare Maintenance Issues in IBD". Great Debates and Updates in IBD, CME. New York, NY. March 2012
43. "Combination therapy should not be continued indefinitely in IBD". Great Debates and Updates in IBD, CME. New York, NY. March 2012
44. "Challenging Cases in IBD". Great Debates and Updates in IBD, CME. New York, NY. March 2012
45. "Vaccination Issues in Patients with IBD". Mt. Sinai School of Medicine, Gastroenterology Grand Rounds. New York, NY. March 2012
46. "Healthcare Maintenance Issues In IBD". Cedars-Sinai Medical Center, Gastroenterology Annual CME Conference. Los Angeles, CA, March 2012
47. "Quality of Care in IBD". Digestive Disease Week, American Gastroenterology Association. San Diego, CA. May 2012
48. "Update in Inflammatory Bowel Disease". Torrance Memorial Hospital, Department of Medicine Grand Rounds. Torrance, CA. July 2012
49. Mastering Clinical Challenges and Emerging Therapies in IBD, CME Invited Lecture. "Understanding quality indicators in IBD: What we know and how do we implement it into our practices? Chicago, IL, July 2012
50. American College of Rheumatology, Annual Meeting "Vaccination issues in rheumatologic disease" Washington, D.C., November 2012
51. "Discussing risks and benefits of therapy with patients" CCFA Conference, New York, November 2012
52. "Vaccination and healthcare maintenance in IBD." CCFA Conference, Nashville, TN. November 2012
53. "Tough management decisions in IBD" Advances in Inflammatory Bowel Diseases Clinical & Research Conference, Hollywood, FL, December 2012
54. "Navigating the healthcare system for patients with IBD." Advances in Inflammatory Bowel Diseases Clinical & Research Conference, Hollywood, FL, December 2012
55. "Meet the professor breakfast: Healthcare maintenance for IBD" Advances in Inflammatory Bowel Diseases Clinical & Research Conference, Hollywood, FL, December 2012
56. "Vaccination issues in inflammatory bowel disease." CCFA Conference, Atlanta, GA, March 2013.
57. "Vaccinations in IBD – who, what, and when?" Minnesota Gastroenterology. May, 2013.
58. "Meet the professor luncheon: Preventable complications in IBD." Orlando, FL May 2013
59. "Vaccination issues in dermatology patients on biologics." Society of Dermatology, Vancouver, British Columbia., June 1, 2013
60. "Update in ulcerative colitis" Dearborne, MI. CME meeting. June 2013.
61. "Quality improvement in IBD" Oxford, England September 10, 2013
62. "Difficult patient management decisions in IBD." Advances in Inflammatory Bowel Diseases Clinical & Research Conference, Hollywood, FL, December 2013

63. "Complications of anti-TNF therapy", moderator of expert panel. Advances in Inflammatory Bowel Diseases Clinical & Research Conference, Hollywood, FL, December 2013
64. "Quality Improvement in IBD – the US Perspective". European Crohn's and Colitis Organization, Copenhagen, Denmark, February 2014
65. "Women's health in IBD", moderator. Cedars-Sinai Annual Update in Gastroenterology. March, 2014, Los Angeles, CA
66. "Health Maintenance for Patients with IBD: Who, When, and What?" Gastroenterology Grand Rounds, Beth Israel Medical Center, New York (March 2014)
67. "Quality improvement for Adults with IBD". IBD2020-USA meeting, New Orleans, LA. (May 2014)
68. "Post-Digestive Disease Week Update – What's new in IBD?" Southern California Society of Gastroenterology, Laguna Beach, CA (June 2014)
69. "Health Maintenance in IBD: Keeping up with Quality". Great Debates in IBD, San Francisco, CA (March 2015)
70. "Thiopurine monotherapy for IBD – Pro" Great Debates in IBD, San Francisco, CA (March 2015)
71. Board Review for Gastroenterology. Great Debates in IBD, San Francisco, CA (March 2015)
72. "Quality improvement in IBD through Patient Engagement". CSMC GI Grand Rounds (March 2015)
73. Acing the GI Boards – IBD. CSMC Annual Gastroenterology update (March, 2015)
74. "Immunization issues in IBD". Portland Gastroenterology Grand Rounds, Portland, OR (October, 2014)
75. "How to institute QI into your practice" CCFA Advances in IBD, Orlando, FL (December, 2014)
76. "Quality reporting for colonoscopy in IBD" CCFA Advances in IBD, Orlando, FL (December, 2014)
77. "Development and implementation of a quality improvement program in IBD" CSMC Health Services Research Grand Rounds (April 2015)
78. "Meet the Professor Luncheon: How to Improve Quality of Care for IBD" Digestive Disease Week, Washington, DC (May 2015)
79. "Quality Measurement in IBD: Past, Present, and Future" Digestive Disease Week, Washington, DC (May 2015)
80. "Innovation Challenges and Biosimilar Considerations for Gastroenterology: Reference Products and Biosimilars". Washington DC (May 2015)
81. "Disease Monitoring and Health Maintenance in IBD". Washington DC (May, 2015)
82. "Quality improvement in IBD" American College of Gastroenterology, Postgraduate Course (Oct 2015, Honolulu, HI)
83. "How can we use quality improvement methodology to implement changes that will help us better care for our patients?" Advances in IBD Clinical and Research Conference, Orlando, FL (Dec 2015)
84. "Strategies for the prevention and treatment of opportunistic infections in IBD patients." Advances in IBD Clinical and Research Conference, Orlando, FL (Dec 2015)
85. "Patient Metrics in IBD", Vienna, Austria (Dec, 2015)
86. "De-escalation strategies in IBD; if, how, and when?". Cedars Sinai 16th Annual GI Meeting, Los Angeles, CA (March, 2016)
87. "Biosimilar therapy for IBD: Promises and Pitfalls" Cedars Sinai 16th Annual GI Meeting, Los Angeles, CA (March, 2016)
88. "Evolving payment models that will affect the way you practice" Digestive Disease Week, San Diego, CA (May, 2016)
89. Mastering Clinical Challenges and Emerging Therapies in IBD. "What are the factors that should influence choice of first therapy in IBD? Understanding longitudinal severity" Chicago, IL (July 2016)
90. Mastering Clinical Challenges and Emerging Therapies in IBD. "Quality of care in IBD: How do you get it in your practice? Chicago, IL, (July 2016)
91. Gastro West Summit. "IBD therapeutics: what's our goal, what are our emerging tools?" Pasadena, CA Oct 2016
92. "Positioning immunomodulators as monotherapies or in combination with biologics" Advances in IBD Clinical and Research Conference, Orlando, FL (2016).

93. "GI tract infections in IBD: Detection and treatment of clostridia difficile, CMV and enteric pathogens: Case studies." Advances in IBD Clinical and Research Conference, Orlando, FL (2016)
94. "Immunomodulators for IBD in 2017: Relevant or Passe?" Gastroenterology grand rounds, CSMC (March, 2017).
95. "Linking Quality and Reimbursement in IBD". DDW, Chicago, IL (May, 2017)
96. "Monitoring drug and disease complications in IBD patients" DDW, Chicago, IL (May, 2017).
97. "Quality improvement collaboratives in North America". 2nd Asia America Assembly of IBD, Beijing, China (June, 2017)
98. "Measuring quality of care for IBD – improvement, accountability, or value?" 2nd Asia America Assembly of IBD, Beijing, China (June, 2017)
99. "Novel approaches to improve caregiver-patient interactions using integrated models" Advances in IBD, Orlando FL (November, 2017).
100. "Separating Myth from Fact: Current Perspectives in the Management of Ulcerative Colitis" Satellite Symposium, Advances in IBD, Orlando, FL (November, 2017)
101. "Deciphering an IBD Operative Report: What Every Gastroenterologist Should Know" (moderator). Advances in IBD, Orlando, FL (November 2017)
102. "What do you do and what do you tell your IBD patients traveling the world?" Advances in IBD, Orlando, FL (November 2017)
103. "mHealth IBD: Self-Management Apps and Decision Aids." Satellite Symposium at Crohn's and Colitis Congress, Las Vegas (January 2018)
104. "Nutrition in IBD" (moderator and course director) Satellite Symposium at Crohn's and Colitis Congress (January 2018)
105. "What Do I Do with This Level? Therapeutic Drug Monitoring in IBD" Cedars-Sinai 18th Annual Meeting in Gastroenterology, Los Angeles, CA (March, 2018)
106. "Is there a role for immunomodulators in 2018?" Rocky Mountain IBD Course, Park City, UT (March, 2018)
107. "Health Maintenance, Preventive Care, and Quality Improvement in IBD" Rocky Mtn. IBD, Park City, UT (March, 2018)
108. "Inflammatory Bowel Disease: the Role of the IBD Nurse" Chinese Crohn's and Colitis Foundation, Hangzhou, China (March, 2018)
109. "Quality of Care in IBD" Chinese Crohn's and Colitis Foundation, Hangzhou, China (March, 2018)
110. "Healthcare maintenance in ulcerative colitis" (satellite symposium, Digestive Disease Week, June 2018)
111. [pending] "Predictors of Response to Biologic Therapy" Japanese Digestive Disease Week, Kobe, Japan, Nov 1, 2018 (invited)

CSMC Teaching Activities

Clinical Teaching:

Jan 2007 – Jan 2009 General Gastroenterology / IBD Inpatient Consultation Team – Attending
2 consecutive weeks, 2 times/year (4 weeks/year)

Jan 2009 - present Inflammatory Bowel Disease (IBD) Inpatient Consultation Team - Attending
2 consecutive weeks, 4 times/year (6-14 weeks/year)

July 2013 – present Inflammatory bowel disease ambulatory clinic – weekly clinical teaching

Non-Clinical Teaching:

Nov, 2005	David Geffen School of Medicine at UCLA, 2 nd year class “Microscopic Colitis”
May, 2006	Cedars-Sinai Medical Center, Resident Lecture Series “Gastroenterology Board Review”
August 2006	Cedars-Sinai Medical Center, Resident Lecture Series “Gastrointestinal Bleeding”
Nov 2006	UCLA GI Fellowship Lecture Series “The 2 nd Opinion IBD Consultation”
May 2007	Cedars-Sinai Medical Center, Resident Lecture Series “Gastroenterology Board Review”
Mar 2009	Cedars-Sinai Medical Center, PhD Graduate Program Lecture “Clinical Trials and Endpoints for Inflammatory Bowel Disease”
May 2009	UCLA GI Fellowship Lecture “The 2 nd Opinion IBD Consultation”
June 2009	Cedars-Sinai Medical Center, Resident Lecture Series “Gastroenterology Board Review”
Nov 2009	David Geffen School of Medicine at UCLA, 2 nd year. “Inflammatory Bowel Disease”
April 2010	UCLA GI Fellows Lecture Series “Clinical Trials and Endpoints in IBD”
April 2010	UCLA GI Fellows Lecture Series “Vaccination Issues in Patients with IBD”
Nov 2010	David Geffen School of Medicine at UCLA, 2 nd year. “Inflammatory Bowel Disease”
Apr 2011	UCLA GI Fellows Lecture “The IBD 2 nd Opinion Consultation”
Sept 2012	UCLA GI Fellows Lecture “Management of patients hospitalized with ulcerative colitis”
Sept 2012	UCLA GI Fellows Lecture “Prevention of Complications in IBD”
Sept 2013	Cedars Sinai Medical Center, Ob-Gyn Grand Rounds. “Fertility and Pregnancy in Women with Inflammatory Bowel Disease.”
October 2013	Cedars Sinai Medical Center, Dept of Medicine Grand Rounds. “Preventive Care in Inflammatory Bowel Disease.”
May, 2015	“IBD and Pregnancy”. CSMC Maternal-Fetal Medicine
Sept 2015	“Care of the hospitalized patient with IBD”. Internal Medicine Residency Lecture series
June 2016	“Management of ulcerative colitis in the hospital” CSMC GI Fellowship Program
2017 - 2018	IBD Core Lecture Series: Vaccinations in Patients with IBD
2017-2018	Mentoring journal club (once a year)

Course Lecturer (UCLA Medical Students):

2009	HBD407 Gastrointestinal, Endocrine & Reproductive Medicine II “Inflammatory bowel disease”
2010	HBD407 Gastrointestinal, Endocrine & Reproductive Medicine II “Inflammatory bowel disease”
2011	HBD407 Gastrointestinal, Endocrine & Reproductive Medicine II “Inflammatory bowel disease”
2012	HBD407 Gastrointestinal, Endocrine & Reproductive Medicine II “Inflammatory bowel disease”
2013	HBD407 Gastrointestinal, Endocrine & Reproductive Medicine II “Inflammatory bowel disease”
2014	HBD407 Gastrointestinal, Endocrine & Reproductive Medicine II “Inflammatory bowel disease”

PUBLICATIONS**Research Papers-Peer Reviewed**

1. Litwin M, **Melmed GY**, Nakazon T. Life after radical prostatectomy: a longitudinal study. *Journal of Urology* 2001 Aug;166(2):587-92.
2. **Melmed GY**, Reid K, Kwon L, Litwin M. Quality of life at the end of life: Trends in patients with metastatic prostate cancer. *Urology* 2002 Jan;59(1):103-9.

3. **Melmed G**, Thomas LS, Lee N, Tesfay SY, Lukasek K, Michelsen KS, Zhou Y, Hu B, Arditi M, Abreu MT. Human intestinal epithelial cells are broadly unresponsive to Toll-like receptor 2-dependent bacterial ligands: implications for host-microbial interactions in the gut. *Journal of Immunology*. 2003 Feb 1;170(3):1406-15.
4. Dubois RW, **Melmed GY**, Henning JM, Laine L. Guidelines for the appropriate use of NSAIDS, COX-2 selective inhibitors, and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy. *Alimentary Pharmacology and Therapeutics*. 2004 Jan 15;19(2):197-208
5. Dubois RW, **Melmed GY**, Henning JM. Risk of upper gastrointestinal injury and events in patients treated with COX-1/COX-2 Non-Steroidal Anti-inflammatory Drugs (NSAIDs), COX-2 selective NSAIDs, and gastro-protective co-therapy: An appraisal of the literature. *Journal of Clinical Rheumatology* 2004 Aug; 10(4): 178-189
6. **Melmed GY**, Ippoliti AF, Papadakis KA, Tran TT, Birt JL, Lee SK, Frenck RW, Targan SR, Vasiliauskas EA. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. *Am J Gastroenterol*. 2006 Aug;101(8):1834-40.
7. Shane M. Devlin, Huiying Yang, Andrew Ippoliti, Kent D. Taylor, Carol J. Landers, Xiaowen Su, Maria T. Abreu, Konstantinos A. Papadakis, Eric A. Vasiliauskas, **Melmed GY**, Phillip R. Fleshner, Ling Mei, Jerome I. Rotter, Stephan R. Targan. *NOD2* Variants and Antibody Response to Microbial Antigens in Crohn's Disease Patients and their Unaffected Relatives. *Gastroenterology* 2007 Feb;132(2):576-86
8. Dubois RW, Aguilar D, Fass R, Orr WC, Elfants AB, Dean BB, Harper AS, Yu HT, **Melmed GY**, Lynn R, Singh A, Tedeschi M. Consequences of frequent nocturnal gastro-oesophageal reflux disease among employed adults: symptom severity, quality of life and work productivity. *Aliment Pharmacol Ther* 2007 (25):487-500
9. **Melmed GY**, Robert Elashoff, Gary C. Chen, Igor Nastaskin, Konstantinos A. Papadakis, Eric A. Vasiliauskas, Weiqing Liu, Carol Landers, Andrew F. Ippoliti, Stephan R. Targan. Predicting a Change in Diagnosis From Ulcerative Colitis to Crohn's Disease: A Nested, Case-Control Study. *Clinical Gastroenterology and Hepatology* 2007 May;5(5):602-8
10. **Melmed GY**, Phillip Fleshner, Ovunc Bardakcioglu, Andrew Ippoliti, Eric A. Vasiliauskas, Konstantinos A. Papadakis, Marla Dubinsky, Jerome I. Rotter, Carol Landers, Stephan R. Targan. Family History and Serology Predict Crohn's Disease after Ileal Pouch Anal Anastomosis for Ulcerative Colitis. *Diseases of Colon and Rectum* (2008 Jan;51(1):100-8; Epub Dec 18, 2007)
11. **Melmed GY**, Shane M. Devlin, George Vlotides, Deepti Dhall, Soraya Ross, Run Yu, Shlomo Melmed. Anti-Aging Therapy with Human Growth Hormone Associated with Metastatic Colon Cancer in a Patient with Crohn's Colitis. *Clinical Gastroenterology and Hepatology* (2008) Mar;6(3):360-3. Epub 2008 Feb 6

12. Brennan M.R. Spiegel, **Melmed GY**, Sean Robbins, Eric Esrailian. Biomarkers and health-related quality of life in end-stage renal disease: A systematic review. *Clinical Journal of the American Society of Nephrology* (2008) Nov; 3(6):1759-68
13. Pimentel M, Hwang L, **Melmed GY**, Low K, Vasiliauskas E, Ippoliti A, Yang J, Lezcano S, Conklin JL, Sahakian A. New Clinical Method for Distinguishing D-IBS from Other Gastrointestinal Conditions Causing Diarrhea: The LA/IBS Diagnostic Strategy. *Dig Dis Sci*. 2009 Jan 24.
14. Brennan M.R. Spiegel, Wayne Ho, Eric Esrailian, , Marla Dubinsky, Peter Higgins, Corey Siegel, Stephan Targan, **Melmed GY**. Controversies in Ulcerative Colitis: A National Survey Comparing Decision-Making of Experts versus Community Gastroenterologists. *Clinical Gastroenterology and Hepatology* 2009 Feb;7(2):168-74
15. Hwang L, Low K, Khoshini R, **Melmed G**, Sahakian A, Makhani M, Pokkunuri V, Pimentel M. Evaluating Breath Methane as a Diagnostic Test for Constipation-Predominant IBS. *Dig Dis Sci*. 2009 Mar 18
16. Murrell ZA, **Melmed GY**, Ippoliti A, Vasiliauskas EA, Dubinsky M, Targan SR, Fleshner PR. A prospective evaluation of the long-term outcome of ileal pouch-anal anastomosis in patients with inflammatory bowel disease-unclassified and indeterminate colitis. *Dis Colon Rectum*. 2009 May;52(5):872-8.
17. **Melmed GY**, Kar S, Geft I, Lo S. Closure of gastrocolonic fistula using cardiac septal defect closure device: A New Method. *Gastrointestinal Endoscopy*, Sept 2009 70:3: 542-45.
18. Yosef Nasser, **Gil Melmed**, Hanlin L. Wang, Zuri Murrell, Eric Vasiliauskas, Marla Dubinsky, Andrew Ippoliti, Dermot McGovern, Stephan Targan, Phillip Fleshner. Rigorous Histopathologic Assessment of the Colectomy Specimen in Patients with Inflammatory Bowel Disease-Unclassified Does Not Predict Outcome After Ileal Pouch-Anal Anastomosis Epub *American J Gastro* 2010 Jan;105(1):155-61
19. Ippoliti A, Devlin S, Mei L, Yang H, Papadakis KA, Vasiliauskas EA, McGovern DP, Abreu MT, **Melmed G**, Shaye O, Enayati P, Chen G, Choi J, Taylor K, Landers CJ, Rotter JI, Targan SR. Combination of innate and adaptive immune alterations increased the likelihood of fibrostenosis in Crohn's disease. *Inflamm Bowel Dis*. 2009 Dec 21. [Epub ahead of print]
20. **Melmed GY**, Agarwal N, Frenck R, Ippoliti AF, Ibanez P, Papadakis KA, Simpson P, Barolet-Garcia C, Ward J, Targan SR, Vasiliauskas EA. Immunosuppression Impairs Response to Pneumococcal Polysaccharide Vaccination in Patients With Inflammatory Bowel Disease. *American J Gastro* 2010 Jan;105(1):148-54.
21. Murrell Z, Vasiliauskas E, **Melmed G**, Lo S, Targan S, Fleshner P. Preoperative wireless capsule endoscopy does not predict outcome after ileal pouch-anal anastomosis. *Dis Colon Rectum*. 2010 Mar;53(3):293-300.

22. McGovern DP, Gardet A, Törkvist L, Goyette P, Essers J, Taylor KD, Neale BM, Ong RT, Lagacé C, Li C, Green T, Stevens CR, Beauchamp C, Fleshner PR, Carlson M, D'Amato M, Halfvarson J, Hibberd ML, Lördal M, Padyukov L, Andriulli A, Colombo E, Latiano A, Palmieri O, Bernard EJ, Deslandres C, Hommes DW, de Jong DJ, Stokkers PC, Weersma RK; NIDDK IBD Genetics Consortium, Sharma Y, Silverberg MS, Cho JH, Wu J, Roeder K, Brant SR, Schumm LP, Duerr RH, Dubinsky MC, Glazer NL, Haritunians T, Ippoliti A, **Melmed GY**, Siscovick DS, Vasiliauskas EA, Targan SR, Annese V, Wijmenga C, Pettersson S, Rotter JI, Xavier RJ, Daly MJ, Rioux JD, Seielstad M. Genome-wide association identifies mulcerative colitis susceptibility loci. *Nat Genet.* 2010 Apr;42(4):332-7. Epub 2010 Mar 14.
23. **Melmed GY**, Spiegel BM, Bressler B, Cheifetz AS, Devlin SM, Harrell LE, Irving PM, Jones J, Kaplan GG, Kozuch PL, Velayos FS, Baidoo L, Sparrow MP, Siegel CA. The appropriateness of concomitant immunomodulators and anti-TNF agents for Crohn's disease: One size does not fit all. *Clin Gastroenterol Hepatol.* 2010 Aug;8(8):655-659
24. McGovern DP, Jones MR, Taylor KD, Marciante K, Yan X, Dubinsky M, Ippoliti A, Vasiliauskas E, Berel D, Derkowski C, Dutridge D; International IBD Genetics Consortium, Fleshner P, Shih DQ, **Melmed G**, Mengesha E, King L, Pressman S, Haritunians T, Guo X, Targan SR, Rotter JI. Fucosyltransferase 2 (FUT2) non-secretor status is associated with Crohn's disease. *Hum Mol Genet.* 2010 Sep 1;19(17):3468-76
25. White E, **Melmed GY**, Vasiliauskas EA, Dubinsky M, Berel D, Targan SR, Fleshner PR. A prospective analysis of clinical variables, serologic factors, and outcome of ileal pouch-anal anastomosis in patients with backwash ileitis. *Dis Colon Rectum.* 2010 Jul;53(7):987-94.
26. Haritunians T, Taylor KD, Targan SR, Dubinsky M, Ippoliti A, Kwon S, Guo X, **Melmed GY**, Berel D, Mengesha E, Psaty BM, Glazer NL, Vasiliauskas EA, Rotter JI, Fleshner PR, McGovern DP. Genetic predictors of medically refractory ulcerative colitis. *Inflamm Bowel Dis.* 2010 Nov;16(11):1830-40
27. Haritunians T, Jones MR, McGovern DP, Shih DQ, Barrett RJ, Derkowski C, Dubinsky MC, Dutridge D, Fleshner PR, Ippoliti A, King L, Leshinsky-Silver E, Levine A, **Melmed GY**, Mengesha E, Vasiliauskas EA, Ziaee S, Rotter JI, Targan SR, Taylor KD. Variants in ZNF365 isoform D are associated with Crohn's disease. *Gut.* 2011 Jan 21. [Epub ahead of print]
28. Nasser Y, Kohanzadeh S, Murrell Z, Berel D, **Melmed G**, Fleshner P. Phantom publications among applicants to a colorectal surgery residency program. *Dis Colon Rectum.* 2011 Feb;54(2):220-5.
29. Zaghayan K, **Melmed G**, Murrell Z, Fleshner P. Are high-dose perioperative steroids necessary in patients undergoing colorectal surgery treated with steroid therapy within the past 12 months? *Am Surg.* 2011 Oct;77(10):1295-9
30. Agarwal N, Ollington K, Kaneshiro M, Frenck R, **Melmed GY**. Are immunosuppressive medications associated with decreased responses to routine immunizations? A systematic review. *Vaccine.* 2012 Feb 14;30(8):1413-24.

31. Ollington KF, Brelan D, Morgan J, Le Q, Fleshner P, **Melmed GY**. Comparison of adenoma detection rates between gastroenterologists and colorectal surgeons. *Am Surg*, 2012 Feb; 78(2):269-70 PubMed PMID:22369845
32. Cheifetz A, **Melmed GY**, Spiegel BMR, Talley J, Devlin S, Harrell L, Irving P, Jones J, Kaplan GG, Kozuch P, Sparrow M, Velayos F, Baidoo L, Bressler B, Siegel CA. Setting priorities for comparative effectiveness research in inflammatory bowel disease: Results of an international provider survey, expert rand panel, and patient focus groups. *Inflamm Bowel Dis*. 2012 Feb 15. PubMed PMID: 22337359
33. White EC, **Melmed GY**, Vasiliauskas E, Dubinsky M, Ippoliti A, McGovern D, Targan S, Fleshner P. Does preoperative immunosuppression influence unplanned hospital readmission after surgery in patients with Crohn's disease? *Dis Colon Rectum*. 2012 May;55(5):563-8. PubMed PMID: 22513435.
34. Zaghiyan K, **Melmed G**, Murrell Z, Fleshner P. Safety and feasibility of using low-dose perioperative intravenous steroids in inflammatory bowel disease patients undergoing major colorectal surgery: A pilot study. *Surgery*. 2012 Apr 11. [Epub ahead of print] PubMed PMID: 22503320.
35. Le Q, **Melmed G**, Dubinsky M, McGovern D, Vasiliauskas EA, Murrell Z, Ippoliti A, Shih D, Kaur M, Targan S, Fleshner P. Surgical outcome of ileal pouch-anal anastomosis when used intentionally for well-defined Crohn's disease. *Inflamm Bowel Dis*. 2012 Mar 29. [Epub ahead of print] PubMed PMID: 22467562.
36. Zaghiyan KN, Murrell Z, **Melmed GY**, Fleshner PR. High-dose perioperative corticosteroids in steroid-treated patients undergoing major colorectal surgery: necessary or overkill? *Am J Surg*. 2012 Jun 28. PubMed PMID:22748293
37. Surti B, Spiegel B, Ippoliti A, Vasiliauskas EA, Simpson P, Shih DQ, Targan SR, McGovern DP, **Melmed GY**. Assessing Health Status in Inflammatory Bowel Disease Using a Novel Single-Item Numeric Rating Scale. *Dig Dis Sci*. 2012 Dec 19. PubMed PMID: 23250673
38. Mayer L, Pandak WM, **Melmed GY**, Hanauer SB, Johnson K, Payne D, Faleck H, Hariri RJ, Fischkoff SA. Safety and Tolerability of Human Placenta-Derived Cells (PDA001) in Treatment-Resistant Crohn's Disease: A Phase 1 Study. *Inflamm Bowel Dis*. 2013 Mar;19(4):754-760. PubMed PMID: 23429460
39. **Melmed GY**, Siegel CA, Spiegel BM, Allen JI, Cima R, Colombel JF, Dassopoulos T, Denson LA, Dudley-Brown S, Garb A, Hanauer SB, Kappelman MD, Lewis JD, Lynch I, Moynihan A, Rubin DT, Sartor RB, Schwartz RM, Wolf DC, Ullman TA. Quality Indicators for Inflammatory Bowel Disease: Development of Process and Outcome Measures. *Inflamm Bowel Dis*. 2013 Mar;19(3):662-668. PubMed PMID: 23388547.
40. Zaghiyan K, **Melmed GY**, Berel D, Ovsepyan G, Murrell Z, Fleshner P. A Prospective, Randomized, Noninferiority Trial of Steroid Dosing After Major Colorectal Surgery. *Ann Surg*. 2013 Jun 14. [Epub ahead of print] PubMed PMID: 23774314

41. Siegel CA, Allen JI, **Melmed GY**. Translating Improved Quality of Care Into an Improved Quality of Life for Patients With Inflammatory Bowel Disease. *Clin Gastroenterol Hepatol*. 2013 Jun 5. PubMed PMID: 23747710.
42. Min SB, Le-Carlson M, Singh N, Nylund CM, Gebbia J, Haas K, Lo S, Mann N, **Melmed GY**, Rabizadeh S, Dubinsky MC. Video Capsule Endoscopy Impacts Decision Making in Pediatric IBD: A Single Tertiary Care Center Experience. *Inflamm Bowel Dis*. 2013 Sep;19(10):2139-45.
43. Nagaraja V, Hays RD, Khanna PP, Spiegel BM, Chang L, **Melmed GY**, Bolus R, Khanna D. Construct validity of the Patient Reported Outcomes Measurement Information System (PROMIS®) gastrointestinal symptom scales in systemic sclerosis. *Arthritis Care Res (Hoboken)*. 2014 Nov;66(11):1725-30
44. Bradford K, **Melmed GY**, Fleshner P, Silverman N, Dubinsky MC. Significant Variation in Recommendation of Care for Women of Reproductive Age with Ulcerative Colitis Postileal Pouch-Anal Anastomosis. *Dig Dis Sci*. 2014 Jun;59(6):1115-20 PubMed PMID: 24549832
45. Weizman A, Huang B, Berel D, Targan SR, Dubinsky M, Fleshner P, Ippoliti A, Kaur M, Panikkath D, Brant S, Oikonomou I, Duerr R, Rioux J, Silverberg M, Rotter JI, Vasiliauskas E, Haritunians T, Shih D, Li D, **Melmed GY**, McGovern DP. Clinical, serologic, and genetic factors associated with pyoderma gangrenosum and erythema nodosum in inflammatory bowel disease patients. *Inflamm Bowel Dis*. 2014 Mar;20(3):525-33.
46. Khanna P, Agarwal N, Khanna D, Hays RD, Chang L, Bolus R, **Melmed G**, Whitman CB, Kaplan RM, Ogawa R, Snyder B, Spiegel BM. Development of an online library of patient-reported outcome measures in gastroenterology: the GI-PRO database. *Am J Gastroenterol*. 2014 Feb;109(2):234-48.
47. Cohen E, Bolus R, Khanna D, Hays RD, Chang L, **Melmed GY**, Khanna P, Spiegel B. GERD Symptoms in the General Population: Prevalence and Severity Versus Care-Seeking Patients. *Dig Dis Sci*. 2014 Oct;59(10):2488-96. [Epub ahead of print]
48. Horton, Dezfoli, Berel, Hirsch, Murthy, Grein, Ippoliti, McGovern, Kaur, Shih, Dubinsky, Targan, Fleshner, Vasiliauskas, **Melmed GY**. Patients with Inflammatory Bowel Disease (IBD) hospitalized with *Clostridium difficile* infection (CDI) should be treated with Vancomycin. *Antimicrob Agents Chemother*. 2014 Sep;58(9):5054-9 PMID 24913174
49. Spiegel BM, Reid MW, Bolus R, Whitman CB, Talley J, Dea S, Shahedi K, Karsan H, Teal C, **Melmed GY**, Cohen E, Fuller G, Yen L, Hodgkins P, Erder MH. Development and validation of a disease-targeted quality of life instrument for chronic diverticular disease: the DV-QOL. *Qual Life Res*. 2015 Jan;24(1):163-79 (Jul 25. [Epub ahead of print]) PubMed PMID: 25059533.
50. Lau C, Dubinsky M, **Melmed G**, Vasiliauskas E, Berel D, McGovern D, Ippoliti A, Shih D, Targan S, Fleshner P. The Impact of Preoperative Serum Anti-TNF α Therapy Levels on Early Postoperative Outcomes in Inflammatory Bowel Disease Surgery. *Ann Surg*. 2015 Mar;261(3):487-96 Jun 19. [Epub ahead of print] PubMed PMID: 24950263.

51. Singh N, Rosenthal CJ, **Melmed GY**, Mirocha J, Fariior S, Callejas S, Tripuraneni B, Rabizadeh S, Dubinsky MC. Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease. *Inflamm Bowel Dis*. 2014 Oct;20(10):1708-13. PubMed PMID: 25153505
52. Spiegel BM, Hays RD, Bolus R, **Melmed GY**, Chang L, Whitman C, Khanna PP, Paz SH, Hays T, Reise S, Khanna D. Development of the NIH Patient-Reported Outcomes Measurement Information System (PROMIS) gastrointestinal symptom scales. *Am J Gastroenterol*. 2014 Nov;109(11):1804-14. doi: 10.1038/ajg.2014.237. Epub 2014 Sep 9. PubMed PMID: 25199473; PubMed Central PMCID: PMC4285435.
53. Weizman AV, Huang B, Targan S, Dubinsky M, Fleshner P, Kaur M, Ippoliti A, Panikkath D, Vasiliauskas E, Shih D, McGovern DP, **Melmed GY**. Pyoderma Gangrenosum among Patients with Inflammatory Bowel Disease: A Descriptive Cohort Study. *J Cutan Med Surg*. 2014 Oct;18(5):361. PubMed PMID: 25277124.
54. Hazlewood GS, Rezaie A, Borman M, Panaccione R, Ghosh S, Seow CH, Kuenzig E, Tomlinson G, Siegel CA, **Melmed GY**, Kaplan GG. Comparative Effectiveness of Immunosuppressants and Biologics for Inducing and Maintaining Remission in Crohn's Disease: A Network Meta-analysis. *Gastroenterology*. 2015 Feb;148(2):344-354.e5. Epub 2014 Oct 16. PubMed PMID: 25448924.
55. Shah ED, Siegel CA, Chong K, **Melmed GY**. Patients with Crohn's Disease Are More Likely to Remain on Biologics than Immunomodulators: A Meta-Analysis of Treatment Durability. *Dig Dis Sci*. 2015 Mar 14 PubMed PMID: 25772778.
56. Sandborn WJ, **Melmed GY**, McGovern DP, Loftus EV Jr, Choi JM, Cho JH, Abraham B, Gutierrez A, Lichtenstein G, Lee SD, Randall CW, Schwartz DA, Regueiro M, Siegel CA, Spearman M, Kosutic G, Pierre-Louis B, Coarse J, Schreiber S. Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn's disease: analyses from the 7-year PRECiSE 3 study. *Aliment Pharmacol Ther*. 2015 Jun 1.. [Epub ahead of print] PubMed PMID: 26031921.
57. **Melmed GY**, Pandak WM, Casey K, Abraham B, Valentine J, Schwartz D, Awais D, Bassan I, Lichtiger S, Sands B, Hanauer S, Richards R, Oikonomou I, Parekh N, Targan S, Johnson K, Hariri R, Fischkoff S. Human Placenta-derived Cells (PDA-001) for the Treatment of Moderate-to-severe Crohn's Disease: A Phase 1b/2a Study. *Inflamm Bowel Dis*. 2015 May 15. [Epub ahead of print] PubMed PMID: 25985246.
58. Dezfoli S, Horton HA, Thepyasuwan N, Berel D, Targan SR, Vasiliauskas EA, Dubinsky M, Shih DQ, Kaur M, McGovern DP, Ippoliti A, Feldman EJ, **Melmed GY**. Combined Immunosuppression Impairs Immunogenicity to Tetanus and Pertussis Vaccination Among Patients with Inflammatory Bowel Disease. *Inflamm Bowel Dis*. 2015 May 15. [Epub ahead of print] PubMed PMID: 25985242.
59. Parekh NK, McMaster K, Nguyen DL, Shah S, Speziale A, Miller J, **Melmed G**. Coping strategies Used by Adult Patients with Inflammatory Bowel Disease. *South Med J*. 2015 Jun;108(6):337-42. PubMed PMID: 26079458.

60. Jones JL, Kaplan GG, Peyrin-Biroulet L, Baidoo L, Devlin S, **Melmed GY**, Tanyingoh D, Raffals L, Irving P, Kozuch P, Sparrow M, Velayos F, Bressler B, Cheifetz A, Colombel JF, Siegel CA. Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti-TNF Therapy for Crohn's Disease: A Meta-analysis of Placebo-controlled Trials. *Clin Gastroenterol Hepatol*. 2015 Dec;13(13):2233-2240 PubMed PMID: 26142167
61. Ahmed S, **Melmed G**, McGovern D, Robbins LA, Shih D, Vasiliauskas E, Singh N, Rabidzadeh S, Ippoliti A, Targan S, Fleshner P. Nonbloody Diarrhea but Not Significant Weight Loss at Diagnosis Is Associated with the Development of Denovo Crohn's Disease After Ileal Pouch-anal Anastomosis for Ulcerative Colitis. *Inflamm Bowel Dis*. 2015 Nov 20. PubMed PMID: 6595552
62. Afghani E, Pandol SJ, Shimosegawa T, Sutton R, Wu BU, Vege SS, Gorelick F, Hirota M, Windsor J, Lo SK, Freeman ML, Lerch MM, Tsuji Y, **Melmed GY**, Wassef W, Mayerle J. Acute Pancreatitis-Progress and Challenges: A Report on an International Symposium. *Pancreas*. 2015 Nov;44(8):1195-210. PubMed PMID: 26465949.
63. Taleban S, Li D, Targan SR, Ippoliti A, Brant SR, Cho JH, Duerr RH, Rioux JD, Silverberg MS, Vasiliauskas EA, Rotter JI, Haritunians T, Shih DQ, Dubinsky M, **Melmed GY**, McGovern DP. Ocular Manifestations in Inflammatory Bowel Disease Are Associated with Other Extra-intestinal Manifestations, Gender, and Genes Implicated in Other Immune-related Traits. *J Crohns Colitis*. 2016 Jan;10 (1):43-9. PubMed PMID: 26449790.
- *Key role in design/analysis of the study*
64. Taleban S, Van Oijen MG, Vasiliauskas EA, Fleshner PR, Shen B, Ippoliti AF, Targan SR, **Melmed GY**. Colectomy with Permanent End Ileostomy Is More Cost-Effective than Ileal Pouch-Anal Anastomosis for Crohn's Colitis. *Dig Dis Sci*. 2016 Feb;61(2):550-559. PubMed PMID: 26434930.
65. Kaur M, Panikkath D, Yan X, Liu Z, Berel D, Li D, Vasiliauskas EA, Ippoliti A, Dubinsky M, Shih DQ, **Melmed GY**, Haritunians T, Fleshner P, Targan SR, McGovern DP. Perianal Crohn's Disease is Associated with Distal Colonic Disease, Stricturing Disease Behavior, IBD-Associated Serologies and Genetic Variation in the JAK-STAT Pathway. *Inflamm Bowel Dis*. 2016 Apr;22(4):862-9. PMID: 26937622.
66. Shah ED, Siegel CA, Chong K, **Melmed GY**. Evaluating Study Withdrawal Among Biologics and Immunomodulators in Treating Ulcerative Colitis: A Meta-analysis of Controlled Clinical Trials. *Inflamm Bowel Dis*. 2016 Apr;22(4):933-9. PubMed PMID: 26818417.
67. **Melmed GY**, Irving PM, Jones J, Kaplan GG, Kozuch PL, Velayos FS, Baidoo L, Sparrow MP, Bressler B, Cheifetz AS, Devlin SM, Raffals LE, Casteelle NV, Mould D, Colombel JF, Dubinsky M, Sandborn WJ, Siegel CA. Appropriateness of Testing for Anti-Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of Results. *Clin Gastroenterol Hepatol*. 2016 May 14. S1542-3565(16) PubMed PMID: 27189916.
68. Devlin SM, **Melmed GY**, Irving PM, Rubin DT, Kornbluth A, Kozuch PL, Raffals LE, Velayos FS, Sparrow MP, Baidoo L, Bressler B, Cheifetz AS, Jones J, Kaplan GG, Siegel CA. Recommendations

for Quality Colonoscopy Reporting for Patients with Inflammatory Bowel Disease: Results from a RAND Appropriateness Panel. *Inflamm Bowel Dis.* 2016 Jun;22(6):1418-24. PubMed PMID: 27057680.

69. Koh SZ, Zaghiyan KN, Li Q, Rabizadeh S, **Melmed GY**, Targan SR, Fleshner PR. Clinical Factors Associated with the Development of Crohn's Disease in Inflammatory Bowel Disease-unclassified Patients Undergoing Ileal Pouch-anal Anastomosis. *Inflamm Bowel Dis.* 2016 Jun;22(6):1397-402. PMID: 26978722.
70. Katz S, **Melmed G**. How Relative Value Units Undervalue the Cognitive Physician Visit: A Focus on Inflammatory Bowel Disease. *Gastroenterol Hepatol (N Y).* 2016 Apr;12(4):240-4. PubMed PMID: 27231455;
71. Robbins L, Zaghiyan K, **Melmed G**, Vasiliauskas E, Ahmed S, McGovern D, Rabizadeh S, Singh N, Landers C, Ippoliti A, Shih D, Targan S, Fleshner P. Outcomes with Anti-Tumor Necrosis Factor-Alpha Therapy and Serology in Patients with denovo Crohn's Disease after Ileal Pouch Anal Anastomosis. *J Crohns Colitis.* 2016 Jul 27. [Epub ahead of print] PubMed PMID: 27466172
72. Targan SR, Feagan B, Vermeire S, Panaccione R, **Melmed GY**, Landers C, Li D, Russell C, Newmark R, Zhang N, Chon Y, Hsu YH, Lin SL, Klekotka P. A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn's Disease. *Am J Gastroenterol.* 2016 Nov;111(11):1599-1607. PMID: 27481309.
73. Tinsley A, Ehrlich OG, Hwang C, Issokson K, Zapala S, Weaver A, Siegel CA, **Melmed GY**. Knowledge, Attitudes, and Beliefs Regarding the Role of Nutrition in IBD Among Patients and Providers. *Inflamm Bowel Dis.* 2016 Oct;22(10):2474-81. PMID: 27598738.
74. Cleveland NK, Rodriquez D, Wichman A, Pan I, **Melmed GY**, Rubin DT. Many Inflammatory Bowel Disease Patients Are Not Immune to Measles or Pertussis. *Dig Dis Sci.* 2016 Oct;61(10):2972-6. PMID: 27557706.
75. Hou JK, Gasche C, Drazin NZ, Weaver SA, Ehrlich OG, Oberai R, Zapala S, Siegel CA, **Melmed G**. Assessment of Gaps in Care and the Development of a Care Pathway for Anemia in Patients with Inflammatory Bowel Diseases. *Inflamm Bowel Dis.* *Inflamm Bowel Dis.* 2017 Jan;23(1):35-43 PMID: 27749376.
76. Shah ED, Farida JP, Siegel CA, Chong K, **Melmed GY**. Risk for Overall Infection with Anti-TNF and Anti-integrin Agents Used in IBD: A Systematic Review and Meta-analysis. *Inflamm Bowel Dis.* 2017 Apr;23(4):570-577. PubMed PMID: 28230558.
77. Johnson LC, **Melmed GY**, Nelson EC, Holthoff MM, Weaver SA, Morgan TS, Siegel CA. Fostering Collaboration Through Creation of an IBD Learning Health System. *Am J Gastroenterol.* 2017 Mar;112(3):406-408. PubMed PMID: 28195179.
78. Farraye FA, **Melmed GY**, Lichtenstein GR, Kane SV. ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease. *Am J Gastroenterol.* 2017 Feb;112(2):241-258. PubMed PMID: 28071656.

79. Parekh NK, Shah S, McMaster K, Speziale A, Yun L, Nguyen DL, **Melmed G**, Kane S. Effects of caregiver burden on quality of life and coping strategies utilized by caregivers of adult patients with inflammatory bowel disease. *Ann Gastroenterol.* 2017;30(1):89-95. PubMed PMID: 28042243
80. Lee AD, Spiegel BM, Hays RD, **Melmed GY**, Bolus R, Khanna D, Khanna PP, Chang L. Gastrointestinal symptom severity in irritable bowel syndrome, inflammatory bowel disease and the general population. *Neurogastroenterol Motil.* 2016 Dec 16. [Epub ahead of print] PubMed PMID: 27981684.
81. Lee CK, **Melmed GY**. Multidisciplinary Team-Based Approaches to IBD Management: How Might "One-Stop Shopping" Work for Complex IBD Care? *Am J Gastroenterol.* 2017 May 16. [Epub ahead of print] PubMed PMID: 28508869.
82. IsHak WW, Pan D, Steiner AJ, Feldman E, Mann A, Mirocha J, Danovitch I, **Melmed GY**. Patient-Reported Outcomes of Quality of Life, Functioning, and GI/Psychiatric Symptom Severity in Patients with Inflammatory Bowel Disease (IBD). *Inflamm Bowel Dis.* 2017 May;23(5):798-803. PubMed PMID: 28301432.
83. Khanna D, Hays RD, Shreiner AB, **Melmed GY**, Chang L, Khanna PP, Bolus R, Whitman C, Paz SH, Hays T, Reise SP, Spiegel B. Responsiveness to Change and Minimally Important Differences of the Patient-Reported Outcomes Measurement Information System Gastrointestinal Symptoms Scales. *Dig Dis Sci.* 2017 May;62(5):1186-1192.. Epub 2017 Mar 1. PubMed PMID: 28251500.
84. Nguyen GC, Boland K, Afif W, Bressler B, Jones JL, Weizman AV, Fowler S, Halder S, Huang VW, Kaplan GG, Khanna R, Murthy SK, Ruel J, Seow CH, Targownik LE, Chawla T, Guimaraes L, Fernandes A, Saleh S, **Melmed GY**. Modified Delphi Process for the Development of Choosing Wisely for Inflammatory Bowel Disease. *Inflamm Bowel Dis.* 2017 Jun;23(6):858-865. PubMed PMID: 28509817.
85. Yoon SM, Haritunians T, Chhina S, Liu Z, Yang S, Landers C, Li D, Ye BD, Shih D, Vasiliauskas EA, Ippoliti A, Rabizadeh S, Targan SR, **Melmed GY**, McGovern DPB. Colonic Phenotypes Are Associated with Poorer Response to Anti-TNF Therapies in Patients with IBD. *Inflamm Bowel Dis.* 2017 Aug;23(8):1382-1393. PubMed PMID: 28590340
86. Almario CV, Keller MS, Chen M, Lasch K, Ursos L, Shklovskaya J, **Melmed GY**, Spiegel BMR. Optimizing Selection of Biologics in Inflammatory Bowel Disease: Development of an Online Patient Decision Aid Using Conjoint Analysis. *Am J Gastroenterol.* 2018 Jan;113(1):58-71. Epub 2017 Dec 5. PubMed PMID: 29206816.
87. Rolston VS, Boroujerdi L, Long MD, McGovern DPB, Chen W, Martin CF, Sandler RS, Carmichael JD, Dubinsky M, **Melmed GY**. The Influence of Hormonal Fluctuation on Inflammatory Bowel Disease Symptom Severity-A Cross-Sectional Cohort Study. *Inflamm Bowel Dis.* 2018 Jan 18;24(2):387-393. PubMed PMID: 29361085.
88. Gu P, Kapur A, Li D, Haritunians T, Vasiliauskas E, Shih DQ, Targan SR, Spiegel BM, McGovern DP, Black JT, **Melmed GY**. Serological, genetic and clinical associations with increased health-care

resource utilization in inflammatory bowel disease. *J Dig Dis*. 2018 Jan;19(1):15-23. PubMed PMID: 29251413.

89. **Melmed GY**, Kaplan GG, Sparrow MP, Velayos FS, Baidoo L, Bressler B, Cheifetz AS, Devlin SM, Irving PM, Jones J, Kozuch PL, Raffals LE, Siegel CA. Appropriateness of Combination Therapy in Inflammatory Bowel Disease: One Size Still Does Not Fit All. *Clin Gastroenterol Hepatol*. 2018 Mar 2. S1542-3565(18)30224-6. [Epub ahead of print] PubMed PMID: 29505910
90. Lee CK, **Melmed GY**, Mann A, Danovitch I, Hedrick R, McGovern DPB, Targan S, Shih D, Vasiliauskas E, IsHak WW, Feldman E. A Multidisciplinary Approach to Biopsychosocial Care for Adults With Inflammatory Bowel Disease: A Pilot Study. *Inflamm Bowel Dis*. 2018 Jun 15. doi: 10.1093/ibd/izy215. [Epub ahead of print] PubMed PMID: 29920581.
91. Winthrop KL, **Melmed GY**, Vermeire S, Long MD, Chan G, Pedersen RD, Lawendy N, Thorpe AJ, Nduaka CI, Su C. Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib. *Inflamm Bowel Dis*. 2018 May 30.. [Epub ahead of print] PubMed PMID: 29850873.
92. Papamichael K, Osterman MT, Siegel CA, **Melmed GY**, Dubinsky MC, Colombel JF, Hanauer SB, Cheifetz AS. Using Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: From an Old Concept to a Future Standard of Care? *Gastroenterology*. 2018 Mar;154(4):1201-1202. Epub 2018 Feb 10. PubMed PMID: 29432749.
93. Melmed GY, Dubinsky MC, Rubin DT, Fleisher M, Pasha SF, Sakuraba A, Tiongco F, Shafran I, Fernandez-Urien I, Rosa B, Papageorgiou NP, Leighton JA. Utility of video capsule endoscopy for longitudinal monitoring of Crohn's disease activity in the small bowel: a prospective study. *Gastrointest Endosc*. 2018 Aug 4. [Epub ahead of print] PubMed PMID: 30086261
94. Lee CK, Melmed GY, Mann A, Danovitch I, Hedrick R, McGovern DPB, Targan S, Shih D, Vasiliauskas E, IsHak WW, Feldman E. A Multidisciplinary Approach to Biopsychosocial Care for Adults With Inflammatory Bowel Disease: A Pilot Study. *Inflamm Bowel Dis*. 2018 Jun 15.

Published Papers – Non- Peer-Reviewed

1. **Melmed GY**. Vaccinations and the utilization of immunosuppressive IBD therapy. *Gastroenterology and Hepatology* 2008 4(12):859-861

Books

1. Spiegel B and Karsan H. (**Melmed**, contributing editor) *Acing the GI Board Exam: IBD Review*. 2013 SLACK Inc

Book Chapters

1. **Melmed GY**. "Ulcerative Colitis." in *Gut Instincts*, Edited by Eric Esrailian. Slack Incorporated, Inc. 2011.
2. Gupta G and **Melmed GY**. "Do we really need to vaccinate all patients with IBD?" in *Clinical Dilemmas in IBD 2nd ed*. Blackwell Publishing, 2011.
3. **Melmed GY**. "Vaccination issues in IBD" in *Clinical Challenges and Complications of IBD*. Edited by Jason Swoger and Miguel Reguero. Slack, Incorporated. (2011) (in press)

4. Horton H, Lee B, **Melmed GY**. Vaccination of Elderly Patients with Gastrointestinal Disorders. Medical Clinics of North America. Edited by Seymour Katz. (Submitted Sept 2013)
5. Horton H, Lee B, **Melmed GY**. Vaccination in Gastrointestinal Disorders. Gastrointestinal Secrets, 5th Edition. Edited by Peter McNalley. (submitted Sept 2013)
6. **Melmed GY**, Targan SR. "Crohn's disease: Clinical Manifestations and Management" in Yamada's Textbook of Gastroenterology, 6th edition. Edited by Daniel Podolsky. Wiley-Blackwell, West Sussex, UK (submitted Jan 2014).
7. Fu YT, **Melmed GY**. "Do patients with IBD really need vaccinations?" in Inflammatory Bowel Disease: A Patient-Centered, Point of Care Reference Guide for Busy Gastroenterology Providers. Springer Science (2015). Daniel Stein and Reza Shaker (Eds).
8. Syal G, Melmed GY. "**IBD Serology in Pouch Disorders**" in Pouchitis and Ileal Pouch Disorders: A Multidisciplinary Approach for Diagnosis and Management. Elsevier (expected 2018). Feza Remzi and Bo Shen (Eds).

Letters to the Editor

1. Simpson PW, **Melmed GY**, Dubinsky M. The impact of medical therapy for inflammatory bowel disease on pregnancy outcome. *Am J Gastroenterol*. 2008; 103:805-6
2. **Melmed GY**, Fleshner PR, Papadakis KA. Proximal small intestinal Crohn's disease detected by capsule endoscopy. *Gastrointest Endosc*. 2008 Jul;68(1):202-3; author reply 203-4.
3. **Melmed GY**. Vaccinations while on thiopurines: some protection is better than none. *Am J Gastroenterol*. 2012 Jan;107(1):141-2. doi: 10.1038/ajg.2011.320.
4. Vu MP, **Melmed GY**, Targan SR. Weeding Out the Facts: The Reality About Cannabis and Crohn's Disease. *Clin Gastroenterol Hepatol*. 2013 Nov 20. pii: S1542-3565(13)01783-7.

Reviews

1. **Melmed GY**, Abreu MT. New insights into the pathogenesis of inflammatory bowel disease. *Current Gastroenterology Reports*. 2004 Dec;6(6):474-81.
2. **Melmed GY**, Lo SK. Capsule Endoscopy: Practical Applications. *Clinical Gastroenterology and Hepatology* 2005; 3:411-422
3. Kaneshiro M, **Melmed GY**. Human Growth Hormone use in Inflammatory Bowel Disease. *Practical Gastroenterology* Feb 2008
4. **Melmed GY**, Stephan R, Targan, Uma Yasothan, Delphine Hanicq, Peter Kirkpatrick. Certolizumab Pegol. *Nature Reviews Drug Discovery*. (August 2008)
5. Sparrow MP, Irving PM, Baidoo L, Bressler B, Cheifetz AS, Devlin SM, Harrell LE, Jones J, Kozuch PL, **Melmed GY**, Velayos FS, Siegel CA. Current controversies in Crohn's disease: A roundtable discussion of the BRIDGe group. *Gastroenterology & Hepatology* 2008; 4(10):713-720.

6. **Melmed GY**. Vaccination strategies for patients with inflammatory bowel disease on immunomodulators and biologics. *Inflamm Bowel Dis*. 2009 May 21 (Invited Review)
7. Siegel CA, **Melmed GY**. Review: Predicting response to anti-TNF agents for the treatment of Crohn's disease. *Therapeutic Advances in Gastroenterology* 2009; 2:245 (Invited Review)
8. **Melmed GY**, Targan SR. Future biologic targets for IBD: potentials and pitfalls. *Nat Rev Gastroenterol Hepatol*. 2010 Feb;7(2):110-7. Review. PubMed PMID: 20134493.
9. Laleh Boroujerdi-Rad and **Melmed GY**. Vaccination issues in patients with IBD. *Practical Gastroenterology*. 2011 April
10. **Melmed GY** and Siegel CA. Quality Improvement in Inflammatory Bowel Disease. *Gastroenterology & Hepatology* Volume 9, Issue 5 May 2013
11. Horton HA, Kim H, **Melmed GY**. Vaccinations in older adults with gastrointestinal diseases. *Clin Geriatr Med*. 2014 Feb;30(1):17-28.
12. Ahmed S, Siegel CA, **Melmed GY**. Implementing quality measures for inflammatory bowel disease. *Curr Gastroenterol Rep*. 2015 Apr;17(4):437. PubMed PMID: 25762473.
13. Berry SK, Siegel CA, **Melmed GY**. Quality Improvement Initiatives in Inflammatory Bowel Disease. *Curr Gastroenterol Rep*. 2017 Aug;19(8):41. Review. PubMed PMID: 28730508
14. Eustace GJ, **Melmed GY**. Therapy for Crohn's Disease: A Review of Recent Developments. *Curr Gastroenterol Rep*. 2018 Apr 5;20(5):19. Review. PubMed PMID: 29623492
15. Lee CK, **Melmed GY**. Multidisciplinary Team-Based Approaches to IBD Management: How Might "One-Stop Shopping" Work for Complex IBD Care? *Am J Gastroenterol*. 2017 Jun;112(6):825-827. Epub 2017 May 16. PubMed PMID: 28508869.
16. Berry SK, **Melmed GY**. Quality indicators in inflammatory bowel disease. *Intest Res*. 2018 Jan;16(1):43-47. doi: 10.5217/ir.2018.16.1.43. Epub 2018 Jan 18. Review. PubMed PMID: 29422796
17. Cohen ER, **Melmed GY**. Making a Case for Patient-Reported Outcomes in Clinical Inflammatory Bowel Disease Practice. *Clin Gastroenterol Hepatol*. 2018 May;16(5):603-607. PubMed PMID: 29678238.
18. Egberg MD, Gulati AS, Gellad ZF, **Melmed GY**, Kappelman MD. Improving Quality in the Care of Patients with Inflammatory Bowel Diseases. *Inflamm Bowel Dis*. 2018 Jul 12;24(8):1660-1669. doi: 10.1093/ibd/izy030. PubMed PMID: 29718299

Editorials

1. **Melmed GY**. Clarithromycin for Crohn's disease: A flash in the pan? (Invited Commentary) *Inflammatory Bowel Disease* Apr;15(4):639-40

2. Siegel CA, **Melmed GY**, Ullman T. Improving Quality of Care in IBD: A STEEEP Challenge. *Inflammatory Bowel Disease*, July 27, 2009
3. **Melmed GY**. Immunizations and IBD: Whose responsibility is it? If I'm the prescribing doctor, shouldn't it be mine? *Inflamm Bowel Dis*. 2012 Jan;18(1):41-2.
4. **Melmed GY**. Do the benefits outweigh the risks of lymphoma associated with combination therapy for IBD Patients? (Published debate against James D. Lewis). *AGA Perspectives* 7(6) December 2011/Jan 2012.
5. Abbasi SQ, **Melmed GY**. Moving on After Discontinuation of Anti-TNF Therapy-What Comes Next? *J Crohns Colitis*. 2018 May 25;12(6):633-634. doi: PubMed PMID: 29701765.

Electronic Articles:

1. **Melmed GY** and McGovern DP. IL-10 Variants in IBD Might Help Identify Likely Responders to Therapy (August 2009) Viewpoints, Medscape Genomic Medicine
<http://www.medscape.com/viewarticle/707932>
2. McGovern DP and **Melmed GY** Genetic Predictors of Treatment-Induced Viral Clearance in Hepatitis C (November 2009). Viewpoints, Medscape Genomic Medicine.
<http://www.medscape.com/viewarticle/712161>
3. **Melmed GY** and McGovern DP. Using Clonal Mutations to Identify Colorectal Cancer in Ulcerative Colitis. (Jan 2010) Viewpoints, Medscape Genomic Medicine
<http://www.medscape.com/viewarticle/714498>
4. **Melmed GY** and McGovern DP. Using Genetic Markers to Predict Response to Anti-TNF Therapy in IBD (April 2010). Viewpoints, Medscape Genomic Medicine
<http://www.medscape.com/viewarticle/719431>
5. McGovern DP and **Melmed GY**. Crohn Disease and CARD15/NOD2. (May 2010). Emedicine WebMD. <http://emedicine.medscape.com/article/1790325-overview>
6. **Melmed GY** and McGovern DP. The Genetics of Celiac Disease: Moving Beyond DQ2 and DQ8 (July, 2010). Viewpoints, Medscape Genomic Medicine.
<http://www.medscape.com/viewarticle/725408>
7. McGovern DP and **Melmed GY**. Progress in genomic research in IBD (September 2010). Viewpoints, Medscape Genomic Medicine
<http://www.medscape.com/viewarticle/728203>
8. **Melmed GY** and McGovern DP. Using Genetics to Predict Prognosis for Ulcerative Colitis (November, 2010). Viewpoints, Medscape Genomic Medicine
<http://www.medscape.com/viewarticle/731814>

9. McGovern DP and **Melmed GY** A Plethora of Susceptibility Genes for Crohn's Disease: What Does It Mean? (December, 2010). Medscape Genomic Medicine.
<http://www.medscape.com/viewarticle/734250>
10. **Melmed GY** and McGovern DP. Risk for Colorectal Cancer in Lynch Syndrome May be Lower than We Thought. (July, 2011). Viewpoints, Medscape Genomic Medicine.
<http://www.medscape.com/viewarticle/745533>
11. McGovern, DP and **Melmed GY**. Pharmacogenomics of PPIs: Clinical Implications. Medscape Genomic Medicine, Practical Pharmacogenomics. (July, 2011)
<http://www.medscape.com/viewarticle/745528>

Abstracts (selected)

1. **Melmed G**, Thomas LS, Lee N, Tesfay SY, Lukasek K, Michelsen KS, Zhou Y, Hu B, Arditi M, Abreu MT. Human intestinal epithelial cells are broadly unresponsive to Toll-like receptor 2-dependent bacterial ligands: implications for host-microbial interactions in the gut. (Poster of Distinction). Digestive Disease Week, San Francisco, May 2002
2. **Melmed GY**, Ippoliti AF, Papadakis KA, Tran TT, Birt JL, Lee SK, Frenck RW, Targan SR, Vasiliauskas EA. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses (Poster). American College of Gastroenterology, Honolulu, HI October 2005
3. **Melmed GY**, Phillip Fleshner, Ovunc Bardakcioglu, Andrew Ippoliti, Eric A. Vasiliauskas, Konstantinos A. Papadakis, Marla Dubinsky, Jerome I. Rotter, Carol Landers, Stephan R. Targan. Family History and Serology Predict Crohn's Disease after Ileal Pouch Anal Anastomosis for Ulcerative Colitis (Poster of Distinction). Digestive Disease Week, Washington DC, May 2007
4. **Melmed GY**, Robert Frenck, Cristina Barolet-Garcia, Patricio Ibanez, Peter Simpson, Konstantinos A. Papadakis, Joel Ward, Andrew Ippoliti, Stephan R. Targan, Eric A. Vasiliauskas 495. TNF blockers and immunomodulators impair antibody responses to pneumococcal polysaccharide vaccine in patients with inflammatory bowel disease (oral presentation). Digestive Disease Week, Washington DC, May 2007
5. **Melmed GY**, Hanlin L. Wang, Eric A. Vasiliauskas, Marla C. Dubinsky, Andrew Ippoliti, Dermot P. McGovern, Stephan R. Targan, Phillip Fleshner W1123. Rigorous Histopathologic Assessment of the Colectomy Specimen for Features of Indeterminate Colitis (IC) Does Not Predict Outcome After Ileal Pouch-Anal Anastomosis (Poster). Digestive Disease Week, Washington DC, May 2007
6. **Melmed GY**, Hanlin L. Wang, Eric A. Vasiliauskas, Marla C. Dubinsky, Andrew Ippoliti, Dermot P. McGovern, Stephan R. Targan, Phillip Fleshner T1174. What Is the Natural History of Inflammatory Bowel Disease-Unclassified (IBDU) After Ileal Pouch Anal Anastomosis (IPAA)? (poster). Digestive Disease Week, Washington DC, May 2007
7. Zuri A. Murrell, Eric A. Vasiliauskas, Marla C. Dubinsky, Andrew Ippoliti, **Melmed GY**, Dermot P. McGovern, Stephan R. Targan, Phillip Fleshner Preoperative Wireless Capsule Endoscopy Does Not Predict Long-Term Outcome After Ileal Pouch-Anal Anastomosis (oral presentation). Digestive Disease Week, Washington DC, May 2007
8. Brennan M. Spiegel, Wayne Ho, Eric Esrailian, **Melmed GY**, Peter D. Higgins, Corey A. Siegel, Marla C. Dubinsky, Stephan R. Targan. Experts and Community Providers Have Varying Beliefs about the Appropriateness of Colectomy for Flat Low Grade Dysplasia (LGD) in Ulcerative Colitis (UC) (poster). Digestive Disease Week, Washington DC, May 2007

9. Patricio Ibanez, Mark Pimentel, **Melmed GY**, Andrew Ippoliti, Stephan R. Targan, Eric A. Vasiliauskas M1154. Fatigue and Abdominal Bloating Predict Small Intestinal Bacterial Overgrowth (SIBO) in Patients with Ulcerative Colitis (UC). (poster). Digestive Disease Week, Washington DC, May 2007
10. Patricio Ibanez, Peter Simpson, **Melmed GY**, Shahab Mehdizadeh, Mamatha Satta, Simon K. Lo 545. Capsule endoscopy (CE) re-assessment in a high volume center (HVC) identifies significant. misinterpretations of the community gastroenterologists (CG) that may impact clinical care. (oral presentation). Digestive Disease Week, Washington DC, May 2007
11. Brennan M. Spiegel, Wayne Ho, Eric Esrailian, **Melmed GY**, Peter D. Higgins, Corey A. Siegel, Marla C. Dubinsky, Stephan R. Targan S1243. Practice Patterns of 5-ASA Use in Ulcerative Colitis (UC): Results of a National Vignette Survey Comparing Experts vs. Community Providers (Poster). Digestive Disease Week, Washington DC, May 2007
12. Yosef Y. Nasser, **Melmed GY**, Thomas Sokol, Beth Moore, Mari Madsen, Zuri A. Murrell, Daniel R. Margulies, Phillip Fleshner Prospective Evaluation of Risk Factors for Thrombosed Hemorrhoids. Digestive Disease Week, Chicago, IL Jun 2009
13. Talin Haritunians, Kent D. Taylor, Jerome I. Rotter, Andrew Ippoliti, Marla Dubinsky, Eric A. Vasiliauskas, **Melmed GY**, Bruce M. Psaty, Stephan R. Targan, Phillip Fleshner, Dermot P. McGovern. Genetic Predictors of Medically Refractive Ulcerative Colitis (UC) Requiring Colectomy (oral presentation). Digestive Disease Week, Chicago, IL Jun 2009
14. Sun-Chuan Dai, Phillip Fleshner, Eric A. Vasiliauskas, Andrew Ippoliti, Dermot P. McGovern, Stephan R. Targan, **Melmed GY**. Adalimumab May Provide Short-Term Improvement in Bowel Movement Frequency for de novo Crohn's Disease After Ileal-Pouch Anal Anastomosis (poster). Digestive Disease Week, Chicago, IL Jun 2009
15. **Melmed GY**, Andrew Ippoliti, Eric A. Vasiliauskas, Dermot P. McGovern, Marla Dubinsky, Peter Simpson, Stephan R. Targan, Brennan M. Spiegel. A Single-Item Numeric Rating Scale Shows Excellent Correlation with Measures of Crohn's Disease Activity and Health-Related Quality of Life (poster). Digestive Disease Week, Chicago, IL Jun 2009
16. Evan White, Marla Dubinsky, **Melmed GY**, Eric A. Vasiliauskas, Andrew Ippoliti, Dermot P. McGovern, Zuri A. Murrell, Stephan R. Targan, Phillip Fleshner. A Prospective Analysis of Clinical Variables, Serologic Factors and Outcome of Ileal Pouch-Anal Anastomosis in Patients with Backwash Ileitis (oral presentation). Digestive Disease Week, Chicago, IL Jun 2009
17. **Melmed GY**, Spiegel BM, Bressler B, Cheifetz AS, Devlin SM, Harrell LE, Irving PM, Jones J, Kozuch PL, Velayos FS, Baidoo L, Sparrow MP, Siegel CA. When is it appropriate to use concomitant immunomodulators with anti-TNF agents for the treatment of Crohn's disease? Results of a RAND Appropriateness Panel (poster). American College of Gastroenterology, San Diego, CA Oct 2009
18. Is There Any Association Between Clinical Features or IBD Seromarker Expression and the Efficacy of Aggressive Medical Therapy of *de novo* Crohn's Disease after Ileal Pouch-Anal Anastomosis (poster). American College of Gastroenterology, San Diego, CA Oct 2009
19. **Melmed GY**, Spiegel BM, Bressler B, Cheifetz AS, Devlin SM, Harrell LE, Irving PM, Jones J, Kozuch PL, Velayos FS, Baidoo L, Sparrow MP, Siegel CA. When is it appropriate to use concomitant immunomodulators with anti-TNF agents for the treatment of Crohn's disease? Results of a RAND Appropriateness Panel (poster). United European Gastroenterology Workshop, London, England Nov 2009
20. Talin Haritunians, Michelle R. Jones, Dermot P. McGovern, Phillip Fleshner, Andrew Ippoliti, Marla Dubinsky, Eric A. Vasiliauskas, **Melmed GY**, David Q. Shih, Robert Barrett, Jerome I. Rotter, Stephan R. Targan, Kent D. Taylor Variants in ZNF365 on 10q21 are associated with Crohn's Disease. Digestive Disease Week, New Orleans, LA (2010)
21. Diana Cheng-Robles, **Melmed GY**, Eric A. Vasiliauskas, Marla Dubinsky, Dermot P. McGovern, Andrew Ippoliti, David Q. Shih, Stephan R. Targan, Phillip Fleshner Preoperative pANCA Expression Influences the Outcome of Ileal Pouch-Anastomosis in Inflammatory Bowel Disease-Unclassified (IBDU). Digestive Disease Week, New Orleans, LA (2010)

22. Diana Cheng-Robles, Dermot P. McGovern, **Melmed GY**, Dror Berel, Eric A. Vasiliauskas, Marla Dubinsky, Andrew Ippoliti, David Shih, Stephan R. Targan, Phillip Fleshner. Genetic Markers Associated with the Development of Denovo Crohn's Disease after Ileal Pouch-Anal Anastomosis. Digestive Disease Week, New Orleans, LA (2010)
23. Daniel Brelan, Dermot P. McGovern, Marla Dubinsky, Dror Berel, David Q. Shih, Andrew Ippoliti, Eric A. Vasiliauskas, Stephan R. Targan, Phillip Fleshner, **Melmed GY**. Unique Predictors of Chronic Pouch Inflammation Among Ulcerative Colitis Patients with Primary Sclerosing Cholangitis (PSC) Undergoing Ileal Pouch-Anal Anastomosis (IPAA). Digestive Disease Week, New Orleans, LA (2010)
24. K. Ollington, D. Brelan, J. Mirocha, J. Morgan, E. Share, P. Fleshner, **G. Melmed**. Does Time Of The Day Affect Polyp Or Adenoma Detection During Colonoscopy At A Private Outpatient Endoscopy Center?. Digestive Disease Week, New Orleans, LA (2010)
25. Robert J. Basseri, Benjamin Basseri, Andrew Ippoliti, Eric A. Vasiliauskas, **Melmed GY**, Stephan R. Targan, Konstantinos A. Papadakis. The efficacy of colorectal cancer surveillance in Crohn's colitis. Digestive Disease Week, New Orleans, LA (2010)
26. Paul D. Anderson, Lily King, Carol J. Landers, Dermot P. McGovern, Ellen Kane, Kent D. Taylor, **Melmed GY**, Virginia L. Kelly, Allison R. Wilcox, Amitabh Srivastava, Corey A. Siegel. Serologic and genetic profiles of patients with incidental asymptomatic ileitis. Digestive Disease Week, New Orleans, LA (2010)
27. Michelle R. Jones, Talin Haritunians, Dermot P. McGovern, Marla Dubinsky, Andrew Ippoliti, Eric A. Vasiliauskas, **Melmed GY**, David Q. Shih, Phillip Fleshner, Arie Levine, Ester Silver Leshinsky, David Siscovick, Kristin D. Marciante, Stephan R. Targan, Jerome I. Rotter, Kent D. Taylor. Genome-Wide Association Study in Ashkenazi Jewish Crohn's Disease Patients Reveals Novel Genes. Digestive Disease Week, New Orleans, LA (2010)
28. Mary Farid, **Melmed GY**, Stephan R. Targan, Andrew Ippoliti, Eric A. Vasiliauskas. The Economically Friendly Mutant: TPMT-Heterozygotes Achieve Therapeutic Levels on Low Doses of 6-MP. Digestive Disease Week, New Orleans, LA (2010)
29. K. Ollington, D. Brelan, J. Mirocha, J. Morgan, E. Share, P. Fleshner, **G. Melmed**. Do Gastroenterologists Find More Adenomas on Colonoscopy than Colorectal Surgeons? Digestive Disease Week, New Orleans, LA (2010)
30. Adam S. Cheifetz, **Melmed GY**, Brennan M. Spiegel, Jennifer Talley, Shane M. Devlin, Laura E. Harrell, Peter M. Irving, Jennifer Jones, Gil G. Kaplan, Patricia L. Kozuch, Miles P. Sparrow, Fernando S. Velayos, Leonard Baidoo, Brian Bressler, Corey A. Siegel. Setting Priorities for Comparative Effectiveness Research in Inflammatory Bowel Disease: Results of an International Provider Survey, Expert RAND Panel, and Patient Focus Groups. American College of Gastroenterology, San Antonio, TX, October 2010
31. Marc Kaneshiro, David Shih, Dermot McGovern, Andrew Ippoliti, Stephan Targan, Eric Vasiliauskas, **Gil Melmed**. Does Upper Endoscopy Impact the Diagnosis or Management of Adults with Colitis? (poster). Advances In IBD: Meeting of the Crohn's Colitis Foundation of America, Miami, FL December 2010
32. Chou J, Vasiliauskas E, Berel D, Feldman E, Ippoliti A, Shih D, McGovern D, Nahm M, Ward J, Targan S, **Melmed GY**. Immunosuppression Does Not Influence the Decay of Pneumococcal Antibodies 3 Years After Vaccination in Patients with Inflammatory Bowel Disease. (Poster of Distinction). Digestive Disease Week, Chicago IL, May 2011
33. Chadwick I. Williams, Allen Greenwood, Evan Norris, Nadine Mokhallati, **Melmed GY**, Dermot P. McGovern, Marla Dubinsky. Fixed Weight Based Thiopurine Dosing Lowers Steroid Free Remission Rates in Crohn's Disease (poster). Digestive Disease Week, Chicago IL, May 2011
34. Minh Nguyen, Kara Bradford, Brian L. Huang, Talin Haritunians, Phillip Fleshner, Eric Himmelfarb, Carol J. Landers, Eric A. Vasiliauskas, Andrew Ippoliti, **Melmed GY**, Marla Dubinsky, Rivkah Gonsky, Jerome I. Rotter, Stephan R. Targan, Dermot P. McGovern, Kent D. Taylor, David Q. Shih. Genetic Predictors of Cytomegalovirus Infection in Patients with Inflammatory Bowel Disease (poster). Digestive Disease Week, Chicago IL, May 2011

35. Arushi M. deFonseka, Talin Haritunians, Dror Berel, Stephan R. Targan, Carol J. Landers, Jerome I. Rotter, Eric A. Vasiliauskas, Andrew Ippoliti, **Melmed GY**, David Q. Shih, Marla Dubinsky, Kent D. Taylor, Dermot P. McGovern. Clinical, Serologic, and Genetic Associations with Low Bone Density in Patients with Inflammatory Bowel Disease (oral presentation). Digestive Disease Week, Chicago IL, May 2011
36. Nir Modiano, Phillip Fleshner, Kent D. Taylor, Marla Dubinsky, Eric A. Vasiliauskas, Andrew Ippoliti, David Q. Shih, **Melmed GY**, Stephan R. Targan, Dror Berel, Talin Haritunians, Jerome I. Rotter, Dermot P. McGovern. Intestinal Granulomas in Crohn's Disease: Association with Patient Characteristics, Serologic Markers, and Genetics (poster). Digestive Disease Week, Chicago IL, May 2011
37. Evan White, **Melmed GY**, Eric A. Vasiliauskas, Marla Dubinsky, Andrew Ippoliti, Dermot P. McGovern, David Q. Shih, Stephan R. Targan, Phillip Fleshner. Does Preoperative Immunosuppression Influence Unplanned Hospital Readmission After Surgery in Patients with Crohn's Disease? (poster). Digestive Disease Week, Chicago IL, May 2011
38. Quy Le, **Melmed GY**, Zuri A. Murrell, Eric A. Vasiliauskas, David Q. Shih, Marla Dubinsky, Andrew Ippoliti, Stephan R. Targan, Phillip Fleshner. Factors Associated with Surgical Outcome of Ileal Pouch-Anal Anastomosis When Intentionally Used in Crohn's Disease (poster). Digestive Disease Week, Chicago IL, May 2011
39. David Kunkel, Robert J. Basseri, Pejman Solaimani, Leo Treyzon, Jeremy Herman, **Melmed GY**, Kathleen Chua, Mark Pimentel. Daily Variation of Bowel Habits Predicts a Diagnosis of IBS Among Patients Referred to a General Gastroenterologist for Evaluation of Chronic Diarrhea: Validation of the La/IBS Diagnostic Strategy (poster). Digestive Disease Week, Chicago IL, May 2011
40. Corey A. Siegel, Phillip Fleshner, Lori S. Siegel, Jerome I. Rotter, Marla Dubinsky, Eric A. Vasiliauskas, Andrew Ippoliti, David Q. Shih, **Melmed GY**, Carol J. Landers, Talin Haritunians, Stephan R. Targan, Kent D. Taylor, Dermot P. McGovern. Predicting Crohn's Disease Post-Operative Recurrence Using Clinical, Endoscopic, Serologic and Genetic Factors (oral presentation). Digestive Disease Week, Chicago IL, May 2011
41. **Melmed GY**, Siegel CA, Spiegel BMR, Allen JA, Dassipoules T, Denson L, Cima R, Colombel JF, Hanauer S, Kappelman M, Lewis JD, Moynihan A, Rubin D, Sartor B, Schwartz R, Wolf D, Ullman T. Defining Quality Indicators for Inflammatory Bowel Disease (IBD): 10 processes to ensure high quality care. American College of Gastroenterology, Washington D.C. October 2011
42. Brian L. Huang MD, **Melmed GY, MD, M.S.**, Julia K. Wegge MD, Karen Shainsky MD, Andrew F. Ippoliti MD, Dermot McGovern MD, Eric Vasiliauskas MD, Philip Fleshner MD, Marla Dubinsky MD, Stephan R. Targan MD, David Q. Shih, MD, PhD. Facial Pyoderma Gangrenosum in Crohn's Disease. American College of Gastroenterology, Washington D.C. October 2011
43. Bradford K, **Melmed GY**, Fleshner P, Dubinsky M. Fertility in women after ileal pouch-anal anastomosis. American College of Gastroenterology, Washington D.C. October 2011.
44. **Melmed, Gil Y.;** Siegel, Corey A.; Spiegel, Brennan M.; Allen, John I.; Cima, Robert R.; Colombel, Jean-Frederic; Dassopoulos, Themistocles; Denson, Lee; Dudley-Brown, Sharon; Garb, Andy; Hanauer, Stephen B.; Kappelman, Michael; Lewis, James D.; Lynch, Isabelle; Moynihan, Amy; Rubin, David T.; Sartor, Ryan B.; Schwartz, Ronald ; Wolf, Douglas C.; Ullman, Thomas A. Development of Process and Outcome Quality Indicators for Inflammatory Bowel Disease (IBD). Digestive Disease Week, San Diego, CA (May, 2012)
45. Dezfoli, Horton, Berel, Ippoliti, McGovern, Kaur, Shih, Dubinsky, Targan, Vasiliauskas, Feldman, **Melmed GY**. Immunomodulators, but not antiTNF therapy, may impair Tetanus and Pertussis booster vaccination responses in adults with inflammatory bowel disease (IBD). Digestive Disease Week, San Diego, CA (May, 2012)
46. Kara Bradford, **Gil Melmed**, Phillip Fleshner, Marla Dubinsky. Significant Variation in Care for Women of Reproductive Age with Ulcerative Colitis. Digestive Disease Week, San Diego, CA (May, 2012)

47. Horton, Dezfoli, Berel, Hirsch, Murthy, Grein, Ippoliti, McGovern, Kaur, Shih, Dubinsky, Targan, Fleshner, Vasiliauskas, **Melmed GY**. Patients with Inflammatory Bowel Disease (IBD) hospitalized with *Clostridium difficile* infection (CDI) should be treated with Vancomycin. Digestive Disease Week, San Diego, CA (May, 2012)
48. Parekh N, Shah S, Yun, Speziale, **Melmed GY**, McMaster, Kane S. Effects of caregiver burden on quality of life and coping strategies utilized by caregivers of adult patients with inflammatory bowel disease. Digestive Disease Week, San Diego, CA (May, 2012)
49. Parekh N, Shah S, Yun, Speziale, **Melmed GY**, McMaster, Kane S. A Study of Coping Strategies Utilized by Adult Patients with Inflammatory Bowel Disease. Digestive Disease Week, San Diego, CA (May, 2012)
50. Huang B, Weizman AV, Berel D, Shih D, Targan S, Dubinsky M, Li D, Kaur M, Haritunians T, Taylor K, **Melmed GY**, McGovern DP. Inflammatory bowel disease and erythema nodosum: clinical, serologic, and genetic associations. Digestive Disease Week, San Diego, CA (May, 2012)
51. Weizman AV, Weizman AV, Berel D, Shih D, Targan S, Dubinsky M, Li D, Kaur M, Haritunians T, Taylor K, **Melmed GY**, McGovern DP. Clinical, serologic, and genetic associations among patients with pyoderma gangrenosum and inflammatory bowel disease. Digestive Disease Week, San Diego, CA (May, 2012)
52. **Melmed GY**, William M. Pandak, Kevin Casey, Bincy P. Abraham, John Valentine, David A. Schwartz, Dahlia Awais, Simon Lichtiger, Isaac Bassan, Stephen Hanauer, Robert Richards, Ioannis Oikonomou, Nimisha Parekh, Stephan Targan, Kristine E. Johnson, Robert J. Hariri, Steven Fischkoff. Human Placenta-Derived Cells (PDA001) for the Treatment of Moderate-to-Severe Crohn's Disease: Results of a Phase 1b/2a Study. American College of Gastroenterology (Las Vegas, NV, October 2012)
53. Levy A, Melmed GY, Vasiliauskas EA. West-Nile virus in a patient with Crohn's disease receiving adalimumab. American College of Gastroenterology (Las Vegas, NV, October 2012)
54. Teng B, **Melmed GY**, Murrell Z, Fleshner P. Does wireless capsule endoscopy affect outcomes after ileal pouch-anal anastomosis in IBD patients treated with anti-TNF agents? Advances in Inflammatory Bowel Disease (Hollywood, FL, December 2012)
55. Rosenthal C, **Melmed G**, Tripuraneni B, Gebbia J, Callejas S, Fariori S, Rabizadeh S, Dubinsky M. Early infliximab trough levels predict remission at one year in pediatric IBD patients. (oral presentation) Advances in Inflammatory Bowel Disease (Hollywood, FL, December 2012)
56. Levy, Anderson, Horton, Sun, Vasiliauskas, Dubinsky, Fleshner, Shih, Kaur, Ippoliti, Targan, Drazin, McGovern, **Melmed GY**. Thromboembolic risk in hospitalized IBD patients is compounded by traditional risk factors and hypercoagulable states. (poster, selected for "best IBD posters tour"). Digestive Disease Week, San Diego, CA (May, 2013)
57. Shah, Chong, Siegel, **Melmed GY**. Patients with Crohn's disease are more likely to remain on biologics than immunomodulators. (poster) Digestive Disease Week, San Diego, CA (May, 2013)
58. Al-Jiboury, Weizman, Berel, Berns, Dubinsky, Targan, Vasiliauskas, Shih, Kaur, Ippoliti, McGovern, **Melmed GY**. Complications and length of stay after cholecystectomy are increased among men with IBD. Digestive Disease Week, San Diego, CA (May, 2013)
59. Cohen, Hays, Bolus, Bolus, Khanna, Chang, Khanna, Spiegel, **Melmed GY**. How well do physicians perceive severity of patients' gastrointestinal symptoms? A comparison across disease states. (poster) Digestive Disease Week, San Diego, CA (May, 2013)
60. Laleh Boroujerdi, Millie D. Long, Dermot McGovern, Wenli Chen, Christopher A. Martin, Robert S. Sandler, John Carmichael, Marla Dubinsky, **Melmed GY**. Symptom Worsening During Pregnancy and Lactation is Associated with Age, Body Mass Index, and Disease Phenotype in Women with Inflammatory Bowel Disease. Digestive Disease Week, San Diego, CA (May, 2013)

61. Laleh Boroujerdi, Millie D. Long, Dermot McGovern, Wenli Chen, Christopher A. Martin, Robert S. Sandler, John Carmichael, Marla Dubinsky, **Melmed GY**. Inflammatory bowel disease symptom severity is influenced by hormone fluctuations in many women with IBD. Digestive Disease Week, San Diego, CA (May, 2013)
62. Lau, Dubinsky, **Melmed GY**, Vasiliauskas, McGovern, Berel, Murrell, Ippoliti, Shih, Kaur, Targan, Fleshner. Influence of biologic agents on short term postoperative complications in patients with Crohn's disease. (poster) Digestive Disease Week, San Diego, CA (May, 2013)
63. Lau, Dubinsky, **Melmed GY**, Vasiliauskas, McGovern, Berel, Murrell, Ippoliti, Shih, Kaur, Targan, Fleshner. Preoperative serum biologic levels do not impact postoperative outcomes in ulcerative colitis. (oral presentation) Digestive Disease Week, San Diego, CA (May, 2013)
64. Lau, Dubinsky, **Melmed GY**, Vasiliauskas, McGovern, Berel, Murrell, Ippoliti, Shih, Kaur, Targan, Fleshner. Higher preoperative serum biologic levels are associated with postoperative complications in Crohn's disease. (oral presentation) Digestive Disease Week, San Diego, CA (May, 2013)
65. Haas, Wachsman, **Melmed GY**, Azizyan, Vasiliauskas, Rosenthal, Kaur, Rabizadeh, Mirocha, Fleshner, Dubinsky. Small bowel ultrasound accurately predicts postoperative endoscopic recurrence in Crohn's disease. (poster) Digestive Disease Week, San Diego, CA (May, 2013)
66. Jones, Kaplan, Peyrin-Biroulet, Baidoo, Devlin, **Melmed GY**, Tanyingoh, Raffals, Irving, Kozuch, Sparrow, Velayos, Bressler, Cheifetz, Colombel, Siegel. Impact of concomitant immunomodulator treatment on efficacy and safety of antiTNF therapy in Crohn's disease: A metanalysis of placebo controlled trials with individual patient-level data. (oral presentation). Digestive Disease Week, San Diego, CA (May, 2013)
67. Chang, Bolus, **Melmed GY**, Hays, Khanna, Khanna, Spiegel. Differences in GI symptom severity between IBS and IBD patients and the general population. (poster) Digestive Disease Week, San Diego, CA (May, 2013)
68. Chang, Bolus, **Melmed GY**, Hays, Khanna, Khanna, Spiegel. Gender and group differences in GI symptom severity between IBS and IBD and the general population (poster). Digestive Disease Week, San Diego, CA (May, 2013)
69. Cohen, Bolus, Khanna, Chang, **Melmed GY**, Khanna, Spiegel. GERD symptoms in the general population: Prevalence and severity Vs. care-seeking patients. (oral presentation). Digestive Disease Week, San Diego, CA (May, 2013)
70. Yoon, Juang, Karsan, **Melmed GY**, Ippoliti, Dubinsky, Kaur, Nguyen, Vora, Fleshner, MCGovern, Targan, Vasiliauskas, Shih. Potential synergism between antiTNF and thiopurine therapy: increased thiopurine metabolites by antiTNF. (poster). Digestive Disease Week, San Diego, CA (May, 2013)
71. Kaur, Panikkath, Li, Berel, Vasiliauskas, Ippoliti, Dubinsky, Shih, **Melmed GY**, Taylor, Fleshner, Targan, McGovern. Perianal Crohn's disease is associated with colonic disease, IBD-related serologies and immune-related genetic variation. (oral presentation). Digestive Disease Week, San Diego, CA (May, 2013)
72. Karsan, Huang, Yoon, Dubinsky, Berel, Yan, **Melmed GY**, Ippoliti, Guo, Taylor, Kaur, Rotter, Targan, Vasiliauskas, McGovern, Shih. Genetic and serologic associations with 6MMP preferential metabolizers reveal novel pathways that may be involved in thiopurine metabolism. (poster). Digestive Disease Week, San Diego, CA (May, 2013)
73. Gerich, Fleshner, Panikkath, Winter, Yoon, Ocampo, Al-Jiboury, Kwon, Haritunians, Berel, Dubinsky, Targan, **Melmed GY**, McGovern. Genotype and postoperative immunosuppression impact surgical recurrence in Crohn's disease. Digestive Disease Week, San Diego, CA (May, 2013)
74. Halloran, **Melmed GY**, Jamil, Lo, Vasiliauskas, Mann. Double balloon enteroscopy assisted stricture dilation delays surgery in patients with small bowel Crohn's disease (poster). Digestive Disease Week, San Diego, CA (May, 2013)

75. Taleban, Li, Targan, Ippoliti, Vasiliauskas, Rotter, Shih, Kaur, Dubinsky, **Melmed GY**, McGovern. Clinical, serologic, and genetic associations in patients with ocular manifestations in IBD. (poster). Digestive Disease Week, San Diego, CA (May, 2013)
76. Halloran, **Melmed GY**, Vasiliauskas, Jamil, Lo, Mann. Diagnostic and therapeutic double balloon enteroscopy in Crohn's disease is safe and effective. Digestive Disease Week, San Diego, CA (May, 2013)
77. Lee S, Taleban S, Targan S, **Melmed G**. E-cigarettes as treatment for medically refractory ulcerative colitis. CCF A Advances in IBD, Hollywood FL (Dec 2013).
78. Eric D. Shah¹, Corey A. Siegel², Kelly Chong³, **Melmed GY** The comparative effectiveness of biologics and immunomodulators for the treatment of ulcerative colitis (oral, Adverse Events Related to IBD Therapy) Digestive Disease Week, Chicago, IL (May, 2014)
79. Talin Haritunians¹, Dalin Li¹, Xiaofei Yan¹, Emebet Mengesha¹, Stephan S. Rich³, Suna Onengut-Gumuscu³, Wei-Min Chen³, David Q. Shih^{1, 2}, XiaoXiao Li¹, Jane F. McGovern¹, Andrew Ippoliti², Marla Dubinsky², Eric A. Vasiliauskas², **Melmed GY**, Phillip Fleshner², Stephan Targan^{1, 2}, Dermot P. McGovern. Genetic variation associated Medically Refractory Ulcerative Colitis requiring colectomy (oral, Genetics of Inflammatory Bowel Disease). Digestive Disease Week, Chicago, IL (May, 2014)
80. Brennan M. Spiegel^{1, 2}, Mark W. Reid^{2, 1}, Roger Bolus^{3, 1}, Cynthia B. Whitman¹, Jennifer Talley^{2, 1}, **Melmed GY**, Erica R. Cohen^{2, 6}, Garth Fuller^{4, 1}, Chassidy Teal⁶, Paul Hodgkins⁸, Stanley K. Dea⁵, Moshe H. Erder⁸, Hetal Karsan⁶ Development and Validation of a Disease-Targeted Quality of Life Instrument for Chronic Diverticular Disease: the DV-QOL (oral, Diverticular Disease: Not what you learned in medical school). Digestive Disease Week, Chicago, IL (May, 2014)
81. Shane M. Devlin¹, **Melmed GY**, Peter M. Irving³, David T. Rubin⁴, Asher Kornbluth⁵, Patricia L. Kozuch⁶, Laura H. Raffals⁷, Fernando S. Velayos⁸, Miles Sparrow⁹, Leonard Baidoo¹⁰, Brian Bressler¹¹, Adam S. Cheifetz¹², Jennifer Jones¹³, Gilaad Kaplan¹, Jennifer Greene¹⁴, Corey A. Siegel¹⁴. Recommendations for Creating a High Quality Endoscopy Report for Inflammatory Bowel Disease Patients: Results from a RAND-Appropriateness Panel (oral, IBD Treatment: New ways of treating and measuring). Digestive Disease Week, Chicago, IL (May, 2014)
82. Jessica L. Yoon¹, Brian L. Huang¹, **Melmed GY**, Jaimin Amin¹, Andrew Ippoliti¹, Marla Dubinsky¹, Puja Khanna¹, Phillip Fleshner¹, Dermot P. McGovern¹, Stephan Targan¹, Eric A. Vasiliauskas¹, David Q. Shih¹ Modulation of thiopurine metabolism by anti-TNF therapy (IBD: Therapeutic Monitoring). Digestive Disease Week, Chicago, IL (May, 2014)
83. Anish V. Patel¹, Phillip Fleshner², **Melmed GY**, Eric A. Vasiliauskas, Systemic Therapy may Mask the Presence of Disease in Colitis Patients Undergoing Preoperative Small Bowel Evaluations (IBD: Natural History and Outcomes). Digestive Disease Week, Chicago, IL (May, 2014)
84. Karen N. Zaghiyan¹, **Melmed GY**, Marla Dubinsky², Eric A. Vasiliauskas², Dermot P. McGovern², Andrew Ippoliti², David Q. Shih², Puja Khanna², Stephan Targan², Phillip Fleshner¹ Medical Prophylaxis After Ileocolic Resection for Crohn's Disease – No Need to Rush (IBD: Uncontrolled Therapeutic Observations in Humans). Digestive Disease Week, Chicago, IL (May, 2014)
85. Brian L. Huang¹, Jaimin Amin¹, Michael J. Stewart¹, Xiaofei Yan¹, Jessica L. Yoon¹, **Melmed GY**, Andrew Ippoliti¹, Eric A. Vasiliauskas¹, Puja Khanna¹, Marla Dubinsky¹, Phillip Fleshner¹, Yodit Alemayehu¹, Stephan Targan¹, Dermot P. McGovern¹, David Q. Shih¹. Genetic and serological predictors of H. pylori infection in patients with inflammatory bowel disease (Helicobacter pylori: Virulence Factors and Pathogenesis). Digestive Disease Week, Chicago, IL (May, 2014)
86. Nancy Fu¹, Xiaofei Yan¹, Talin Haritunians¹, Stephan Targan¹, **Melmed GY**, Eric A. Vasiliauskas¹, Dermot P. McGovern¹. Genetic, Serological and Clinical Associations in Inflammatory Bowel Disease (IBD) Patients with Clostridium difficile Infection (CDI). (IBD: Disease complications). Digestive Disease Week, Chicago, IL (May, 2014)

87. Sandborn W, Schreiber S, Siegel C, **Melmed G**, McGovern D, Pierre-Louis B, Kosutic G, Spearman M. Predictors of Maintenance of Long-Term Remission in Crohn's Disease Patients Treated with Certolizumab Pegol: Multivariate and Univariate Analyses from the PRECiSE 3 Study (American College of Gastroenterology Annual Meeting, October 2014)
88. **Melmed GY**, Ozbay B, Skup M, Siegel C. Analysis of an Administrative Claims Database Suggests Poor Quality of Care for Inflammatory Bowel Disease (American College of Gastroenterology Annual Meeting, October 2014)
89. **Melmed GY**, Peter Irving, Gilaad G. Kaplan, Brian Bressler, Jennifer Jones, Patricia Kozuch, Miles Sparrow, Fernando Velayos, Leonard Baidoo, Adam Cheifetz, Shane Devlin, Laura Raffals, Niels Vande Castele, Diane R. Mould, Marla Dubinsky, Jean-Fred Colombel, William J. Sandborn, Corey Siegel and BRIDGE (Building Research in IBD Globally) THE APPROPRIATENESS OF TESTING AND INTERPRETATION OF ANTI-TNF DRUG CONCENTRATION AND ANTIBODY LEVELS: Development of a mobile application for point of care testing. (American College of Gastroenterology Annual Meeting, October 2014)
90. **Melmed GY**, Peter Irving, Gilaad G. Kaplan, Brian Bressler, Jennifer Jones, Patricia Kozuch, Miles Sparrow, Fernando Velayos, Leonard Baidoo, Adam Cheifetz, Shane Devlin, Laura Raffals, Niels Vande Castele, Diane R. Mould, Marla Dubinsky, Jean-Fred Colombel, William J. Sandborn, Corey Siegel and BRIDGE (Building Research in IBD Globally) THE APPROPRIATENESS OF TESTING AND INTERPRETATION OF ANTI-TNF DRUG CONCENTRATION AND ANTIBODY LEVELS: WHEN SHOULD THEY BE ORDERED, AND WHAT TO DO WITH THE RESULTS? (United European Gastroenterology Week, October 2014)
91. Eric D. Shah¹, Corey A. Siegel², Kelly Chong³, **Gil Melmed**: Anti-TNF agents may pose a higher risk of infection than anti-integrin agents in treating inflammatory bowel disease (Digestive Disease Week, May 2015)
92. Lori Robbins¹, Karen N. Zaghiyan², **Melmed GY**¹, Eric A. Vasiliauskas¹, Dermot McGovern¹, Andrew Ippoliti¹, David Q. Shih¹, Stephan Targan¹, Phillip Fleshner² Do Anti-TNF Agents Work in Ulcerative Colitis Patients with *de novo* Crohn's Disease Who Failed Anti-TNF Therapy Before Ileal Pouch-Anal Anastomosis? (Digestive Disease Week, May 2015)
93. Bradley Morganstern¹, Namita Singh³, Stephan Targan¹, Carol J. Landers¹, Minh Nguyen¹, Eric A. Vasiliauskas¹, David Shih¹, Edward J. Feldman¹, Andrew Ippoliti¹, Dermot McGovern¹, Marla Dubinsky², Shervin Rabizadeh³, **Melmed GY**. Single-Center Experience of Vedolizumab in Patients with Inflammatory Bowel Disease: Does Age Matter? (Digestive Disease Week, May 2015)
94. **Gil Melmed**¹, Dermot McGovern², Stefan Schreiber³, Gordana Kosutic⁵, Marshall Spearman⁴, Jason Coarse⁵, William Sandborn⁶: Early Remission Status as a Predictor of Long-Term Outcome in Crohn's Disease Patients Treated With Certolizumab Pegol: Results of an Analysis from the PRECiSE 3 Study. (Digestive Disease Week, May 2015)
95. Nicholas Manguso, Karen N. Zaghiyan, Galinos Barmparas, Neel K. Mann, Simon K. Lo, **Melmed GY**, Eric A. Vasiliauskas, David Q. Shih, Andrew Ippoliti, Stephan Targan, Phillip Fleshner¹: Long-Term Evaluation of Preoperative Wireless Capsule Endoscopy as a Predictor of Outcome After Ileal Pouch-Anal Anastomosis (Digestive Disease Week, May 2015)
96. Neel K. Mann, Laith H. Jamil, **Melmed GY**, Eric A. Vasiliauskas, Simon K. Lo. Small Bowel Imaging in Crohn's Disease: Measuring the True Accuracy of Proximal and Distal Small Intestinal Disease Activity Using Total Enteroscopy in Patients with Established and Suspected Crohn's Disease (Digestive Disease Week, May 2015)
97. Minh Nguyen, Jonathan S. Pourmorady, Bradley Morganstern, Xiaofei Yan, Alice Zhang, Sundip S. Karsan, Phillip Fleshner, Eric A. Vasiliauskas¹, **Gil Melmed**, Andrew Ippoliti, Stephan Targan Dermot McGovern, David Shih: Genetic Associations with Preferential 6TGN Metabolizers Reveal Novel Pathways Involved in Purine Metabolism (Digestive Disease Week, May 2015)

98. Emily Miraflor, Karen N. Zaghiyan, Galinos Barmparas, **Gil Melmed**, David Shih³, Andrew Ippoliti³, Eric A. Vasiliauskas, Dermot McGovern, Stephan Targan, Phillip Fleshner: *Denovo* Crohn's Disease After Ileal Pouch-Anal Anastomosis for Ulcerative Colitis and Inflammatory Bowel Disease-Unclassified - Long-Term Follow-Up of a Prospective IBD Registry (Digestive Disease Week, May 2015)
99. Yoon SM, Haritunians T, Chhina S, Ye BD, Shih DQ, Vasiliauskas E, Ippoliti A, Targan S, Melmed GY, McGovern D. Factors predicting response to antiTNF agents for patients with inflammatory bowel disease. (Oral presentation no. 188, Digestive Disease Week, May 2016)
100. Stewart MJ, Dubinsky M, Morganstern B, Vasiliauskas E, Targan S, Ippoliti An Shih DQ, Mould D, McGovern D, Melmed GY. The steady-state pharmacokinetics of adalimumab: Do we need to drink from the 'trough'? Sa1965 Digestive Disease Week, May 2016
101. Melmed GY, Dubinsky M, Rubin D, Fleisher M, Pasha SF, Fernandez-Urien I, Rosa B, Papageorgiou N, Bergwerk AJ, Kedar-Datel M, Leighton JA. Utility of capsule endoscopy for monitoring Crohn's disease activity. Tu1984 Digestive Disease Week, May 2016
102. Gu P, Kapur A, Li D, Haritunians T, Vasiliauskas E, Shih DQ, Targan S, Spiegel B, McGovern D, Black J, Melmed GY. Biomarkers may predict higher resource utilization in IBD. Sa1929 Digestive Disease Week, May 2016
103. Bonthala N, Wong M, Kilpatrick S, Melmed GY. Operative vaginal delivery and higher order perineal lacerations do not result in worsening of disease in women with inflammatory bowel disease. Sa1906 Digestive Disease Week, May 2016
104. Kapur Anshika; Divakaran Sonia, Walsh Cynthia, Nguyen Anne, Alacantha Chelsea, Anda Joseph, Curry Yankamma, Adams Patricia, Melmed Gil. The Impact of A Nurse Navigator Program on Telephone Calls and Emergency Department Utilization Among IBD Patients. Advances in IBD Annual Meeting, Orlando, FL Dec 2016
105. Melmed Gil, McCutcheon Adams Kelly, Bray Harry, Caron Jessica, Deitch Joshua, Hirschhorn Gary, Jones Michael, Long Millie, Lum Donald, Rubin David, Shah Samir, Hou Jason, Tinsley Andrew, Turner Quin, Younes Ziad, Walsh Cynthia, Oberai Ridhima, Weaver Alandra, Crate Damara, Siegel Corey. Feasibility of a multicenter, collaborative, longitudinal, quality improvement learning health system for adult IBD care. Advances in IBD Annual Meeting, Orlando, FL Dec 2016 (poster)
106. Hwang Caroline, Reddy Swapna, Issokson Kelly, Giguere-Rich Catherine, Tinsley Andrew, Bray Harry, Lum Donald, Aguilar Humberto, Zisman Timothy, Younes Ziad, Nguyen Anne, Crate Damara, Spinrad Amelia, Oberai Ridhima, Weaver Alandra, Siegel Corey, Melmed Gil. Development of a Clinical Care Pathway to Identify and Treat Malnutrition in Patients with Inflammatory Bowel Disease. Advances in IBD Annual Meeting, Orlando, FL Dec 2016 (poster)
107. Hou Jason, Xu Ang, Weatherly Julie, Sellin Joseph, Kaur Manreet, Gonzalez Iliana, Gonzalez Janette, Cruz Guillermina, Waddy Angela, Velani Shelina, Long Millie, Jones Michael, Turner Quin, Caron Jessica, Crate Damara, McCutcheon Adams Kelly, Oberai Ridhima⁸, Weaver Alandra, Melmed Gil, Siegel Corey. CCFA Quality of Care Breakthrough Series Collaborative: Improving the Delivery of Urgent Care for Patients with IBD . Advances in IBD Annual Meeting, Orlando, FL Dec 2016 (poster)
108. Feasibility of Screening for Anemia using the Crohn's and Colitis Foundation Anemia Care Pathway in IBD Qorus Hou Jason, Weatherly Julie, Sellin Joseph, Kaur Manreet, Metwally Mark, Vrabie Raluca, Ali Tauseef, Kaur Nirmal, Gasche Chris, Drazain Noam, Oberai Ridhima, Nguyen Anne, Weaver Alandra, Siegel Corey, Melmed Gil. Advances in IBD Annual Meeting, Orlando, FL Dec 2016. (poster)
109. Jacobs Jonathan, Tong Maomeng, Ruegger Paul, Li Dalin, Haritunians Talin, Fleshner Phillip, Vasiliauskas Eric, Ippoliti Andrew, Melmed Gil, Shih David, Kaur Manreet, Targan Stephan, Borneman James, McGovern Dermot, Braun Jonathan. The microbiome of the colonic mucosal-luminal interface in Crohn's disease patients in endoscopic remission. Advances in IBD Annual Meeting, Orlando, FL Dec 2016 (poster)

110. Melmed G, Dubinsky M, Rubin D, Fleisher M, Pasha S, Sakuraba A, Tiongco F, Shafran I, Fernandez-Urien I, Rosa B, Papageorgiou N, Leighton J. Longitudinal evaluation with capsule endoscopy for disease monitoring of patients with Crohn's disease is feasible, valid, and safe. Mo1754 Digestive Disease Week, May 2017.
111. Melmed G, Kaplan G, Sparrow M, Velayos F, Baidoo L, Bressler B, Cheifetz A, Devlin S, Irving P, Jones J, Kozuch P, Raffals L, Siegel C. Appropriateness of concomitant immunomodulator and biologic therapy in Crohn's disease and ulcerative colitis. Su1904. Digestive Disease Week, May 2017
112. Gu P, Ko J, Yan X, Li D, Haritunians T, Vasiliauskas E, Targan S, Melmed G, McGovern D, Shih D. Serologic and genetic markers may help predict disease behavior in patients with Crohn's disease. Sa1832 Digestive Disease Week, May 2017
113. Bonthala N, Wong M, Kilpatrick S, Melmed G. Biologic and/or thiopurine use during pregnancy was not associated with increased obstetric injuries or new perianal disease in women with inflammatory bowel disease. Su1883 Digestive Disease Week, May 2017
114. Jacobs J, Tong M, Ruegger P, Li D, Haritunians T, Fleshner P, Vasiliauskas E, Ippoliti A, Melmed G, Shih D, Targan S, Borneman J, McGovern D, Braun J. Crohn's disease, obesity, and high crohn's disease genetic risk are associated with parallel changes in the microbiome of the cecal and sigmoid mucosal-luminal interface. 463 Digestive Disease Week, May 2017
115. Almario CV, Keller M, Mosadeghi S, Martinez B, Whitman C, Lasch K, Ursos L, Melmed G, Spiegel B. Examining patient decision-making surrounding biologic therapies in inflammatory bowel disease: Insights from a conjoint analysis survey. (Poster) American College of Gastroenterology Annual Meeting, Las Vegas, NV Oct 2016.
116. Zhu L, Melmed G, Yan X, Haritunians T, Shih DQ, Vasiliauskas E, Ippoliti, A, Rabizadeh S, Singh N, Targan SR, Liu Z, Li D, McGovern D. UBE2L3, ANCA, ASCA, and CBir1 are associated with mechanisms of non-response to anti-TNF in IBD patients with adequate drug levels. (poster) Digestive Disease Week, Chicago, IL May 2017
117. Gaurav Syal, Nirupama Bonthala, Edward Feldman, Eric A. Vasiliauskas, Dermot P.B. McGovern, Gil Y. Melmed, Philip Fleshner, Stephan R. Targan, David Q. Shih. Pharmacokinetic Effects Of Anti-Tumor Necrosis Factor Agents On Thiopurine Drug Metabolism In Inflammatory Bowel Diseases. Am College Gastro, Nov 2017.
118. Prachi Nene, Welmoed van Deen, Sandra Elmasry, Yun Wang, Alandra Weaver, Corey Siegel, Gil Melmed, Caroline Hwang A SELF-REPORTED MALNUTRITION TOOL PREDICTS HOSPITALIZATION AND SURGERY IN INFLAMMATORY BOWEL DISEASE (poster) Digestive Disease Week, Washington, DC May 2018
119. Phillip Gu, Shishir Dube, Jeffrey Ko, Dalin Li, Talin Haritunians, Eric Vasiliauskas, Gaurav Syal, Nirupama Bonthala, Shaohong Yang, Phillip Fleshner, Gil Melmed, Stephan Targan, Dermot McGovern. CLINICAL, SEROLOGIC, AND GENETIC MARKERS ARE ASSOCIATED WITH COMPLICATED DISEASE BEHAVIOR IN PATIENTS WITH CROHN'S DISEASE (CD) (poster) Digestive Disease Week, Washington, DC May 2018
120. Kevin Winthrop, Gil Melmed, Severine Vermeire, Millie Long, Gary Chan, Ronald Pedersen, Nervin Lawendy, Andrew Thorpe, Chudy Nduaka, Chinyu Su. HERPES ZOSTER INFECTION IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING TOFACITINIB (poster) Digestive Disease Week, Washington, DC May 2018
121. Gaurav Syal, Lori Robbins, Amir Kashani, Nirupama Bonthala, Eric Vasiliauskas, Edward Feldman, Marc Wishingrad, Dermot McGovern, Christina Ha, Stephan Targan, Gil Melmed. HYPOALBUMINEMIA AND BANDEMIA PREDICT FAILURE OF INFLIXIMAB RESCUE THERAPY IN ACUTE SEVERE COLITIS INDEPENDENT OF THE INFLIXIMAB DOSE (poster) Digestive Disease Week, Washington, DC May 2018
122. Sameer Berry, Will Takakura, Catherine Bresee, Gil Melmed. MANAGING INPATIENT PAIN IN IBD: PAIN IS NOT IMPROVED DURING HOSPITALIZATION AND UNAFFECTED BY OPIATES (poster) Digestive Disease Week, Washington, DC May 2018

123. Marcy Akhlaghpour, Talin Haritunians, Emebet Mengesha, Dalin Li, Zhenqiu Liu, Randall McNally, Carol Landers, Karen Zaghiyan, Phillip Fleshner, Gil Melmed, Stephan Targan, Mark Silverberg, Kathrin Michelsen, Dermot McGovern. MULTI-CENTER COHORT ANALYSIS IDENTIFIED A GENETIC ASSOCIATION IN COMPLEMENT FACTOR B WITH PERIANAL CROHN'S DISEASE (poster) Digestive Disease Week, Washington, DC May 2018
124. Chang Kyun Lee, Dalin Li, Talin Haritunians, Stephan Targan, Gil Melmed, Dermot McGovern. MULTI-OMICS ANALYSES IN CROHN'S DISEASE DO NOT INCREMENTALLY PREDICT POOR OUTCOMES OVER ENDOSCOPIC AND SEROLOGIC VARIABLES (poster) Digestive Disease Week, Washington, DC May 2018
125. Jason Hou, Ruifei Wang, Sunina Nathoo, Julie Weatherly, Joseph Sellin, Richa Shukla, Guillermina Cruz, Ridhima Oberai, Corey Siegel, Gil Melmed. REDUCTION IN THE PREVALENCE OF ANEMIA AMONG PATIENTS WITH INFLAMMATORY BOWEL DISEASE AFTER IMPLEMENTATION OF THE ANEMIA CARE PATHWAY (poster) Digestive Disease Week, Washington, DC May 2018
126. Jason Hou, Iliana Gonzalez, Ang Xu, Julie Weatherly, Richa Shukla, Joseph Sellin, Guillermina Cruz, Damara Crate, Kelly McCutcheon Adams, Alandra Weaver, Gil Melmed, Corey Siegel. SUSTAINABLE IMPROVEMENTS IN URGENT CARE ACCESS AND OUTCOMES FOR PATIENTS WITH INFLAMMATORY BOWEL DISEASE THROUGH IMPLEMENTATION OF AN URGENT ACCESS TOOLKIT (poster) Digestive Disease Week, Washington, DC May 2018
127. Caroline Hwang, Welmoed van Deen, Swapna Reddy, Kelly Issokson, Catherine Giguere-Rich, Damara Crate, Andrew Tinsley, Emmanuelle Williams, Donald Lum, Harry Bray, Timothy Zisman, Humberto Aguilar, Alandra Weaver, Ridhima Oberai, Corey Siegel, Gil Melmed, Jennifer Brown. THE FEASIBILITY AND RELIABILITY OF PATIENT-REPORTED MALNUTRITION RISK SCREENING IN INFLAMMATORY BOWEL DISEASE (poster) Digestive Disease Week, Washington, DC May 2018